




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C12N 15/13, C07K 14/705, 16/28, A61K 38/17</b>		<b>A1</b>	(11) International Publication Number: <b>WO 99/25832</b>
			(43) International Publication Date: 27 May 1999 (27.05.99)
(21) International Application Number: PCT/US98/24391		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 16 November 1998 (16.11.98)			
<b>(30) Priority Data:</b> 60/066,063 17 November 1997 (17.11.97) US 09/135,238 17 August 1998 (17.08.98) US			
<b>(71) Applicant:</b> THE BOARD OF TRUSTEES OF LELAND STANFORD JUNIOR UNIVERSITY [US/US]; Office of Technology Licensing, Suite 350, 900 Welch Road, Palo Alto, CA 94304-1850 (US).			
<b>(72) Inventors:</b> NOLAN, Garry, P.; 784 Alester Avenue, Palo Alto, CA 94303 (US). HITOSHI, Yasumichi; 672 Chiquita Avenue #4, Mountain View, CA 94041 (US).			
<b>(74) Agents:</b> BREZNER, David, J. et al.; Flehr, Hohbach, Test, Albritton & Herbert LLP, Suite 3400, 4 Embarcadero Center, San Francisco, CA 94111-4187 (US).		<b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	

(54) Title: TOSO



## (57) Abstract

The present invention is directed to novel polypeptides such as the Toso protein and related molecules which have an inhibitory effect on TNF mediated apoptosis and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

<b>AL</b>	Albania	<b>ES</b>	Spain	<b>LS</b>	Lesotho	<b>SI</b>	Slovenia
<b>AM</b>	Armenia	<b>FI</b>	Finland	<b>LT</b>	Lithuania	<b>SK</b>	Slovakia
<b>AT</b>	Austria	<b>FR</b>	France	<b>LU</b>	Luxembourg	<b>SN</b>	Senegal
<b>AU</b>	Australia	<b>GA</b>	Gabon	<b>LV</b>	Latvia	<b>SZ</b>	Swaziland
<b>AZ</b>	Azerbaijan	<b>GB</b>	United Kingdom	<b>MC</b>	Monaco	<b>TD</b>	Chad
<b>BA</b>	Bosnia and Herzegovina	<b>GE</b>	Georgia	<b>MD</b>	Republic of Moldova	<b>TG</b>	Togo
<b>BB</b>	Barbados	<b>GH</b>	Ghana	<b>MG</b>	Madagascar	<b>TJ</b>	Tajikistan
<b>BE</b>	Belgium	<b>GN</b>	Guinea	<b>MK</b>	The former Yugoslav Republic of Macedonia	<b>TM</b>	Turkmenistan
<b>BF</b>	Burkina Faso	<b>GR</b>	Greece			<b>TR</b>	Turkey
<b>BG</b>	Bulgaria	<b>HU</b>	Hungary	<b>ML</b>	Mali	<b>TT</b>	Trinidad and Tobago
<b>BJ</b>	Benin	<b>IE</b>	Ireland	<b>MN</b>	Mongolia	<b>UA</b>	Ukraine
<b>BR</b>	Brazil	<b>IL</b>	Israel	<b>MR</b>	Mauritania	<b>UG</b>	Uganda
<b>BY</b>	Belarus	<b>IS</b>	Iceland	<b>MW</b>	Malawi	<b>US</b>	United States of America
<b>CA</b>	Canada	<b>IT</b>	Italy	<b>MX</b>	Mexico	<b>UZ</b>	Uzbekistan
<b>CF</b>	Central African Republic	<b>JP</b>	Japan	<b>NE</b>	Niger	<b>VN</b>	Viet Nam
<b>CG</b>	Congo	<b>KE</b>	Kenya	<b>NL</b>	Netherlands	<b>YU</b>	Yugoslavia
<b>CH</b>	Switzerland	<b>KG</b>	Kyrgyzstan	<b>NO</b>	Norway	<b>ZW</b>	Zimbabwe
<b>CI</b>	Côte d'Ivoire	<b>KP</b>	Democratic People's Republic of Korea	<b>NZ</b>	New Zealand		
<b>CM</b>	Cameroon			<b>PL</b>	Poland		
<b>CN</b>	China	<b>KR</b>	Republic of Korea	<b>PT</b>	Portugal		
<b>CU</b>	Cuba	<b>KZ</b>	Kazakstan	<b>RO</b>	Romania		
<b>CZ</b>	Czech Republic	<b>LC</b>	Saint Lucia	<b>RU</b>	Russian Federation		
<b>DE</b>	Germany	<b>LI</b>	Liechtenstein	<b>SD</b>	Sudan		
<b>DK</b>	Denmark	<b>LK</b>	Sri Lanka	<b>SE</b>	Sweden		
<b>EE</b>	Estonia	<b>LR</b>	Liberia	<b>SG</b>	Singapore		

## TOSO

This is a continuing application of U.S.S.N. 60/066,063, filed November 17, 1997.

### FIELD OF THE INVENTION

5 The invention relates to novel Toso proteins, nucleic acids and antibodies. The invention further relates to the use of bioactive agents such as Toso proteins, nucleic acids and antibodies capable of modulating Fas or tumor necrosis factor ("TNF") receptor mediated apoptosis for the diagnosis and treatment of disease.

### BACKGROUND OF THE INVENTION

10 Apoptosis or programmed cell death is an important homeostatic mechanism that maintains cell number, positioning, and differentiation. Several intracellular and intercellular processes are known to regulate apoptosis. One of the best characterized systems is initiated by the cell surface receptor, Fas (Apo-1/CD95), homologues of which initiate apoptosis in a wide range of organisms (Itoh, *et al.*, Cell, **66**:233-243 (1991); Yonehara, *et al.*, J. Exp. Med., **169**:1747-1756 (1989)). Clustering of the Fas cytoplasmic domain generates an apoptotic signal via the  
15 "death domain" (Itoh and Nagata, J. Biol. Chem., **268**:10932-10937 (1993)). Several critical proteins that bind to the death domain or other domains within the cytoplasmic region have been identified using yeast two-hybrid and biochemical screens (Boldin, *et al.*, J. Biol. Chem., **270**:7795-7798 (1995); Chinnaiyan, *et al.*, Cell, **8145**:505-512 (1995); Chu, *et al.*, Proc. Natl. Acad. Sci. USA, **92**:11894-11898 (1995); Okura, *et al.*, J. Immunol., **157**:4277-

4281 (1996); Sato, *et al.*, Science, **268**:411-415 (1995); Stanger, *et al.*, Cell, **8145**:513-523 (1995)).

Fas engagement by Fas ligand is capable of activating the interleukin-1  $\beta$  converting enzyme family of cysteine proteases (Caspases) - the proteolytic executors of apoptosis (Enari, *et al.*, Nature, **375**:78-81 (1995); Enari, *et al.*, Nature, **380**:723-726 (1996); Los, *et al.*, Nature, **375**:81-83 (1995); Tewari and Dixit, J. Biol. Chem., **270**:3255-3260 (1995)). Recent studies implicate caspase8 (MACH/FLICE/Mch5) as linking Fas receptor signaling to downstream caspases via its association with FADD/MORT1 (Boldin, *et al.*, (1995); Chinnaiyan, *et al.*, (1995); Boldin, *et al.*, (1996); Fernandes-Alnemri, *et al.*, Proc. Natl. Acad. Sci. USA, **93**:7464-7469 (1996); Muzio, *et al.*, Cell, **85**:817-827 (1996)). Several groups have reported that caspase-8 activation is inhibited by a cellular inhibitor, cFLIP/FLAME-1/l-FLICE (Irmeler, *et al.*, Nature, **388**:190-195 (1997); Srinivasula, *et al.*, J. Biol. Chem., **272**:18542-18545 (1997); Hu, *et al.*, J. Biol. Chem., **272**:17255-17257 (1997)). Other proteins involved in Fas-mediated apoptosis include: (a) the Fas-activated serine/threonine kinase (FAST kinase), which is rapidly activated during Fas-mediated apoptosis; (b) acid sphingomyelinase, which produces ceramide, a pro-apoptotic signal that acts as a second messenger in several systems; and (c) Daxx, a novel protein that links Fas to the JNK stress kinase pathway (Cifone, *et al.*, J. Exp. Med., **180**:1547-1552 (1994); Tian, *et al.*, J. Exp. Med., **182**:865-874 (1995); Yang, *et al.*, Cell, **89**:1067-1076 (1997)). The exact role of these latter co-activators has yet to be fully defined.

A balance between life and programmed cell death signals in cells is likely to be governed by multiple interacting regulators that counteract apoptotic signals with appropriate anti-apoptotic signals. Imbalances in this regulation can result in wide variety of pathologies, including cancer and immune dysfunction and it is now clear that other polypeptides besides Fas contribute to dysregulation of appropriately induced apoptosis. As an example, in many tumor cell lines Fas expression does not correlate with sensitivity to Fas-induced apoptosis, implying the existence of Fas-resistance protein (Richardson, *et al.*, Eur. J. Immunol., **24**:2640-2645 (1994)). Also, in some types of cells, Fas-induced apoptosis requires protein

synthesis inhibitors such as cycloheximide (Itoh and Nagata, (1993); Yonehara, *et al.*, (1989)) and even in Fas-sensitive cells, protein synthesis inhibitors can play a synergistic role with cycloheximide (Itoh and Nagata, (1993)). These combined observations further suggest the existence of proteins capable of suppressing Fas-generated apoptotic signaling.

- 5      Additionally, in the course of a normal immune response, both cytotoxic T cell and NK cell activation can lead to Fas ligand (FasL) induction of apoptosis in target cells (Arase, *et al.*, J. Exp. Med., **181**:1235-1238 (1995); Berke, Cell, **81**:9-12 (1995); Montel, *et al.*, Cell Immunol., **166**:236-246 (1995)). Although both Fas and FasL are rapidly induced following T-cell activation, activated-T cells remain resistant to Fas-induced apoptosis for several days
- 10     (Klas, *et al.*, Int. Immunol., **5**:625-630 (1993); Owen-Schaub, *et al.*, Cell Immunol., **140**:197-205 (1992)). Thus, a mechanism exists to shield newly activated T cells from the cytotoxicity of their own FasL expression. This is likely to be an important component of T cell activation processes and protection in lymph nodes, splenic germinal centers and other sites at which T cell activation results in apoptosis of target cells.
- 15     Described herein is the identification and characterization of a novel surface molecule, "Toso" which is a member of the immunoglobulin gene superfamily and which specifically inhibits Fas and TNF receptor family mediated apoptosis. The results demonstrate the existence of cell surface mediated signaling pathways that lead to down regulation of Fas-mediated apoptosis in certain cell types and suggest that activation of T cells suppresses
- 20     internal signaling systems that might lead inappropriately to T cell-induced self-killing.

Accordingly, it is an object of the invention to provide Toso proteins and related molecules. It is a further object of the invention to provide recombinant nucleic acids encoding Toso proteins, and expression vectors and host cells containing the nucleic acid encoding the Toso protein. A further object of the invention is to provide methods for screening for antagonists

25     and agonists of Toso.

### SUMMARY OF THE INVENTION

In accordance with the objects outlined above, the present invention provides recombinant nucleic acids encoding a Toso protein that will hybridize under high stringency conditions to the nucleic acid sequence depicted in Figure 1 (SEQ ID NO:1) or its complement.

5 Recombinant nucleic acids encoding Toso proteins that are at least about 70% identical to the amino acid sequence depicted in Figure 1 (SEQ ID NO:1) are also provided, as well as recombinant nucleic acid that is at least about 70% identical to the nucleic acid sequence depicted in Figure 1 (SEQ ID NO:1) or its complement.

10 In a further aspect, the invention provides expression vectors and host cells comprising the nucleic acids of the invention, and processes for producing a Toso protein comprising culturing the host cells under conditions suitable for expression of a Toso protein.

In an additional aspect, the invention provides Toso proteins, and antibodies that bind to Toso proteins.

15 Further provided are methods of modulating apoptosis in a cell comprising administering to the cell a recombinant nucleic acid encoding a Toso protein, and methods for treating an apoptosis related condition in a mammal comprising administering a recombinant nucleic acid encoding a Toso protein.

### BRIEF DESCRIPTION OF THE DRAWINGS

20 Figure 1 depicts the nucleotide sequence (SEQ ID:NO 1) of Toso. Also presented are the positions of the initiator ATG start codon, the stop codon the nucleotides which correspond to the signal sequence and the nucleotides which correspond to the putative transmembrane domain of the Toso protein.

Figure 2a depicts the amino acid sequence (SEQ ID:NO 2) of amino acids 1 to 390 deduced from nucleotides 1 to 1173 of the nucleotide sequence shown in Figure 1 (SEQ ID:NO 1). Two hydrophobic regions are underlined.

Figure 2b depicts a Kyte-Doolittle hydropathy plot analysis of Toso gene product (upper) and schematic presentation of Toso (bottom). The mature Toso is a 390-amino acid protein with the leader sequence of 17 amino acids (hatched bar), the extracellular domain of 236 amino acids (ED), the transmembrane region of 20 amino acids (TM; dotted bar) and the cytoplasmic domain of 117 amino acids (CD). The immunoglobulin domain (Ig), the basic amino acid-rich region (Basic), the proline-rich region (Proline), and the acidic amino acid-rich region (Acidic) are indicated.

Figure 3 depicts BLAST search results using the Toso gene product. The position of the first amino acid in each sequence is given in the left side of the alignment. Gaps are indicated by dashes. Dark and light shading refer to identical and similar residues, respectively. For sequence alignment of the Toso N-terminus, IgVH (G1HUNM), IgV $\lambda$  (L1MS4E), TcR V $\alpha$  (RWMSAV), TCR V $\beta$  (RWHUVY), CD4 (U47924), CD8 chain 11 (X04310), Poly Ig R (QRRBG) and immunoglobulin V-set consensus sequence are shown in the alignment. Arrows indicate positions characteristic of many V-set sequences. The sequence of the Toso cytoplasmic domain is aligned with acid sphingomyelinase, insulin receptor substrate 1 (IRS1) and apoptosis inhibitor, IAP, from *Orgyia pseudotsugata* nuclear polyhedrosis virus (Op-IAP).

Figure 4a depicts the effect of Toso on anti-Fas induced apoptosis. The percentage of apoptotic cells are expressed as the mean (hatched and shaded bar)  $\pm$  SD of triplicate cultures. Apoptotic cells in each culture without anti-Fas mAb were less than 2%.

Figure 4b depicts the effect of Toso on anti-Fas-, staurosporine- and ceramide-induced apoptosis in Jurkat.ecoR cells (closed triangle), Jurkat.ecoR cells infected with

pBabeMN-lacZ (closed square) and pBabeMN-Toso (open circle). The percentage of apoptotic cells are expressed as the mean (symbol)  $\pm$  SD (vertical bar) of triplicate cultures.

Figure 4c depicts the effect of Toso on FADD-induced apoptosis in Jurkat.ecoR cells infected with pBabeMN-Lyt-2- $\alpha'$  (hatched bar), and pBabeMN-Toso (shaded bar). The percentage of apoptotic cells are expressed as the mean (hatched bar or shaded bar)  $\pm$  SD of triplicate cultures.

Figure 4d depicts the effect of Toso on TNF- $\alpha$ -induced apoptosis in Jurkat.ecoR cells. The percentage of apoptotic cells are expressed as the mean (hatched bar or shaded bar)  $\pm$  SD of triplicate cultures.

Figure 4e depicts the effect Toso on anti-Fas mAb-induced apoptosis in cells cultured with ( $\alpha$ -Fas (+)) or without ( $\alpha$ -Fas (-)) 50 ng/ml of anti-Fas mAb. After culture for five days, GFP expression of survived cells were analyzed by FACScan.

Figure 5a depicts the results of Western blot analysis of caspase-8 processing by induction of cFLIP. Jurkat.ecoR cells (control) and pBabeMN-Toso-infected Jurkat.ecoR cells (Toso) were cultured with (+) or without (-) 50 ng/ml of anti-Fas mAb ( $\alpha$ -Fas) for 6 hours. Positions of pro-caspase-8 (Pro), the processed form (p20) and standard marker are indicated.

Figure 5b depicts the results of Western blot analysis of cFLIP expression in Jurkat.ecoR cells (control) and pBabeMN-Toso-infected Jurkat.ecoR cells (Toso).

Figure 6a depicts the effect of Toso deletion mutant expression on anti-Fas mAb-induced apoptosis. Structure of the Toso deletion mutants is shown at the left side of this panel. Full-length Toso is a 390-amino acid protein with the leader sequence of 17 amino acids (hatched bar), the extracellular domain of 236 amino acids (ED), the transmembrane region of 20 amino acids (TM; dark-shaded bar) and the cytoplasmic domain of 117 amino acids (CD).



-7-

The hemagglutinin (HA) tag is indicated as a light shaded bar. The percentage of apoptotic cells is expressed as the mean (hatched and shaded bar)  $\pm$  SD of triplicate cultures.

Figure 6b depicts Western blot analysis of deletion mutants using anti-HA antibody. The molecular weight of major products from Toso.HA, Toso $\Delta$ (377-390).HA, Toso $\Delta$  (334-390).HA, Toso $\Delta$  (252-390). HA, Toso $\Delta$  (281 -390). HA, Toso $\Delta$  (29 187). HA and Lyt-2/Toso(271-390).HA was 60/35, 55/30, 50/26, 40, 38, 35, 60/30 kDa, respectively. Positions and sizes (kDa) of standard protein markers are indicated in left side of panel.

Figure 6c depicts Crosslinking the extracellular domain of Toso. Positions of standard protein markers and Toso.HA are indicated in left side and right of panel, respectively.

Figure 7a depicts mRNA dot blot analysis of Toso gene in several human tissues.

Figure 7b depicts Northern blot analysis of Toso gene in several human immune tissues. Positions and sizes (kbp) of Toso mRNA are indicated in left side of panels.

Figure 7c depicts RT-PCR analysis of Toso in human cell lines (upper panel). Positions and sizes (kbp) of Toso and standard nucleotide makers are indicated. As a control for loading, we amplified  $\beta$ -actin cDNA (lower panels).

Figure 8a depicts (a) Northern blot analysis of Toso gene in Jurkat cells (None) and Jurkat cells stimulated with PMA and PHA (PMA + PHA) or PMA and Ionomycin (PMA + Io.). RNA was electrophoresed, transferred to a Hybond N+ membrane and hybridized with a radiolabelled probe specific for Toso (upper) and  $\beta$ -actin (lower). Film was exposed at  $-70^{\circ}\text{C}$  with an intensifying screen for two days (upper). Positions and sizes (kbp) of Toso mRNA are indicated in right side of panels.

Figure 8b depicts activation induced resistance to anti-Fas mAb-induced apoptosis in Jurkat cells. The percentage of apoptotic cells are expressed as the mean (hatched bar)  $\pm$  SD of triplicate cultures.

Figure 8c depicts the effect of Toso on PMA and ionomycin (PMA + Io.)-induced apoptosis. Jurkat.ecoR cells (-), Jurkat.ecoR cells infected with pBabeMN-lacZ (lacZ), pBabeMN-Toso-infected clones (Toso clones 1-5) were cultured with 10 ng/ml of anti-Fas mAb (left), 10 ng/ml PMA and 500 ng/ml ionomycin (right) for 24 hours. The percentage of apoptotic cells are expressed as the mean (hatched bar and shaded bar)  $\pm$  SD of triplicate cultures.

Figure 9a depicts the RT-PCR analysis of Toso in peripheral blood mononuclear cells after activation with PHA (upper panel, the 1.2 kbp fragment of Toso).

Figure 9b depicts analysis of Toso in peripheral blood mononuclear cells after allogenic stimulation (upper panel, the 1.2 kbp fragment of Toso). Stimulator cells (SC), responder cells (RC) or mixed cells (RC +SC) were cultured for one day (day 1) and six days (day 6).

Figure 10 depicts a model for the role of Toso in T cell activation. In the model, the role of Toso is to be induced following T cell activation and to protect T cells from self-induced programmed cell death. The inhibitory effects of Toso on Fas signaling maps at the level of caspase-8 through induced expression of cFLIP.

Figure 11 depicts massive cell death of 70 Z3 cells induced by TOSO. 70Z/3 cells were incubated with supernatant from  $\phi$ NX-E (closed triangle), viral supernatant of pBabeMN-Lyt-2 $\bar{O}$  (closed square), or pBabeMN-TOSO (open circle) for 12 hours including the initial spinning at 2500 rpm for 90 min. Infection frequency of pBabeMN-Lyt-2 $\bar{O}$  was determined to be 79% at 48 hours post infection. The percentage of viable cells at various time points are expressed as mean (symbol)  $\pm$  SD (vertical bar) of triplicate cultures.

#### DETAILED DESCRIPTION OF THE INVENTION

The present invention provides novel Ig domain-containing Toso polypeptides, with potent pathway-specific anti-apoptotic effects in hematopoietic cells. Toso (named after a Japanese liquor that is drunk on New Year's Day to celebrate long life and eternal youth) exerts an inhibitory activity against apoptosis induced by Fas-, TNF- $\alpha$ -, FADD and PMA/Ionomycin but not against staurosporine- or ceramide-induced apoptosis. Without being bound by theory, the mechanism of blocking apoptotic activation, and the pathway specificity of the effect, is most likely explained by Toso induction of cFLIP expression which inhibits caspase-8 processing. Toso is expressed within lymphoid tissues and hematopoietic cells, and is enhanced after T-cell activation, which suggests an important role for this and related molecules in the immune system.

Accordingly, the present invention provides Toso proteins and nucleic acids. In a preferred embodiment, the Toso proteins are from vertebrates and more preferably from mammals including dogs, cats and rabbits, rodents (including rats, mice, hamsters, guinea pigs, etc.), primates (including chimpanzees, African green monkeys, etc.), farm animals (including sheep, goats, pigs, cows, horses, etc.) and in the most preferred embodiment, from humans. However, using the techniques outlined below, Toso proteins from other organisms may also be obtained.

As outlined herein, the Toso proteins of the present invention are IgG superfamily molecules which are expressed in a variety of tissue types, including, but not limited to lymph nodes, peripheral blood leukocytes, thymus, lung, and kidney. As further outlined herein, Toso proteins exert pathway specific anti-apoptotic effects in hematopoietic cells. Toso is a membrane bound protein, as it contains a putative transmembrane domain. The extracellular domain of Toso has homology to immunoglobulin variable domains.

A Toso protein of the present invention may be identified in several ways. "Protein" in this sense includes proteins, polypeptides, and peptides. A Toso nucleic acid or Toso protein is initially identified by substantial nucleic acid and/or amino acid sequence homology to the

-10-

sequences shown in Figures 1 and 2a. Such homology can be based upon the overall nucleic acid or amino acid sequence.

As used herein, a protein is a "Toso protein" if the overall homology of the protein sequence to the amino acid sequence shown in Figure 2a (SEQ ID NO:2) is preferably greater than  
5 about 50 or 60%, more preferably greater than about 70 or 75%, even more preferably greater than about 80% and most preferably greater than 85%. In some embodiments the homology will be as high as about 90 to 95 or 98%. Homology in this context means sequence similarity or identity, with identity being preferred. Identical in this context means identical amino acids at corresponding positions in the two sequences which are being compared.  
10 Homology in this context includes amino acids which are identical and those which are similar (functionally equivalent). This homology will be determined using standard techniques known in the art, such as the Best Fit sequence program described by Devereux, *et al.*, Nucl. Acid Res., **12**:387-395 (1984), preferably using the default settings, or the BLASTX program (Altschul, *et al.*, J. Mol. Biol., **215**:403-410 (1990)). The alignment may  
15 include the introduction of gaps in the sequences to be aligned. In addition, for sequences which contain either more or fewer amino acids than the proteins shown in the Figures, it is understood that the percentage of homology will be determined based on the number of homologous amino acids in relation to the total number of amino acids. Thus, for example, homology of sequences shorter than that shown in the Figures, as discussed below, will be  
20 determined using the number of amino acids in the shorter sequence.

As outlined herein, Toso proteins have several important domains. Toso contains a cytoplasmic domain from amino acids 273 to 390, with the extracellular domain spanning from 18 to 253 (unless otherwise specified, all amino acid numbering is based on the human sequence). Toso contains a standard transmembrane domain, spanning from amino acids 254  
25 to 272. Toso contains an additional hydrophobic region at the N-terminus, amino acids 1 to 17, corresponding to a putative signal sequence. In addition, the cytoplasmic domain of Toso contains a basic amino acid-rich region (from Arg274 to Arg323), a proline rich region (from Pro334 to P346), and an acidic amino acid-rich region (from Glu378 to Asp384). In addition,

the cytoplasmic domain has partial homology to FAST kinase, acid sphingomyelinase, insulin receptor substrate-1 (IRS-1) and the apoptosis inhibitor from *Orgyia pseudotsugata* nuclear polyhedrosis virus (Op-IAP). The extracellular domain of Toso has homology to the immunoglobulin V-region.

5 As used herein, a protein is also a "Toso protein" if the homology of the cytoplasmic domain comprising amino acids 273 to 390, or the extracellular domain comprising amino acids 18 to 253, respectively, of the amino acid sequence shown in Figure 2a (SEQ ID NO:2) is preferably greater than about 50% or 60%, more preferably greater than about 70% or 75%, even more preferably greater than about 80% and most preferably greater than 85%. In some  
10 embodiments the homology will be as high as about 90 to 95 or 98%.

Toso proteins of the present invention may be shorter or longer than the amino acid sequences shown in the Figures. Thus, in a preferred embodiment, included within the definition of Toso proteins are portions or fragments of the sequences depicted in the Figures. As outlined herein, Toso deletion mutants can be made, including, but not limited to, the  
15 deletion of amino acids 377-390, 334-390, 281-390, 252-390, and 29-187. As further outlined herein, Toso fusion proteins can be made including, but not limited to, the fusion of amino acids 1-271. A preferred Toso fragment is the cytoplasmic domain of Toso, which may modulate apoptosis, as shown herein. A further preferred Toso fragment is the extracellular domain of Toso, comprising roughly the first 236 amino acids of Toso, which is required for  
20 the anti-apoptotic effects on Fas antibody-stimulated cells. However, as outlined herein, preferred fragments of Toso also include a transmembrane domain, as it may be involved in signaling and Fas-induced apoptosis by Toso may require its insertion into membranes.

Thus, in a preferred embodiment, the Toso proteins of the present invention are Toso polypeptides. In this embodiment, a Toso polypeptide comprises at least the immunoglobulin  
25 V-like domain, and preferably a transmembrane domain, although it may contain additional amino acids as well. As shown in the Examples and discussed below, Toso is an IgG

superfamily protein which is capable of inhibiting apoptosis mediated by members of the Fas or TNF receptor family of proteins.

In a preferred embodiment, the Toso proteins are derivative or variant Toso proteins. That is, as outlined more fully below, the derivative Toso peptide will contain at least one amino acid substitution, deletion or insertion, with amino acid substitutions being particularly preferred. The amino acid substitution, insertion or deletion may occur at any residue within the Toso peptide. As outlined below, particularly preferred substitutions are made within the extracellular domain or cytoplasmic domain of the Toso protein.

In addition, as is more fully outlined below, Toso proteins can be made that are longer than those depicted in the figures, for example, by the addition of epitope or purification tags, the addition of other fusion sequences, etc.

Toso proteins may also be identified as being encoded by Toso nucleic acids. Thus, Toso proteins are encoded by nucleic acids that will hybridize to the sequence depicted in Figure 1, or its complement, as outlined herein.

In a preferred embodiment, when the Toso protein is to be used to generate antibodies, the Toso protein must share at least one epitope or determinant with the full length protein shown in Figure 2a. By "epitope" or "determinant" herein is meant a portion of a protein which will generate and/or bind an antibody. Thus, in most instances, antibodies made to a smaller Toso protein will be able to bind to the full length protein. In a preferred embodiment, the epitope is unique; that is, antibodies generated to a unique epitope show little or no cross-reactivity. In a preferred embodiment, the antibodies are generated to an extracellular portion of the Toso molecule, *i.e.* to all or some of the N-terminal region from amino acid numbers 18-253.

In a preferred embodiment, the antibodies to Toso are capable of reducing or eliminating the biological function of Toso, as is described below. That is, the addition of anti-Toso antibodies (either polyclonal or preferably monoclonal) to cells comprising Toso receptors

may reduce or eliminate the Toso receptor activity, blocking the signalling pathway that blocks apoptosis; that is, when Toso receptor function is reduced or eliminated, the cells die. Generally, at least a 50% decrease in activity is preferred, with at least about 75% being particularly preferred and about a 95-100% decrease being especially preferred.

- 5 The Toso antibodies of the invention specifically bind to Toso proteins. By "specifically bind" herein is meant that the antibodies bind to the protein with a binding constant in the range of at least  $10^6$ -  $10^8$  M, with a preferred range being  $10^7$  -  $10^9$  M.

10 In the case of the nucleic acid, the overall homology of the nucleic acid sequence is commensurate with amino acid homology but takes into account the degeneracy in the genetic code and codon bias of different organisms. Accordingly, the nucleic acid sequence homology may be either lower or higher than that of the protein sequence. Thus the homology of the nucleic acid sequence as compared to the nucleic acid sequence of Figure 1 is preferably greater than 50 or 60%, more preferably greater than about 70 to 75%, particularly greater than about 80% and most preferably greater than 85%. In some  
15 embodiments the homology will be as high as about 90 to 95 or 98%.

In a preferred embodiment, a Toso nucleic acid encodes a Toso protein. As will be appreciated by those in the art, due to the degeneracy of the genetic code, an extremely large number of nucleic acids may be made, all of which encode the Toso proteins of the present invention. Thus, having identified a particular amino acid sequence, those skilled in the art  
20 could make any number of different nucleic acids, by simply modifying the sequence of one or more codons in a way which does not change the amino acid sequence of the Toso.

In one embodiment, the nucleic acid homology is determined through hybridization studies. Thus, for example, nucleic acids which hybridize under high stringency to the nucleic acid sequences shown in Figure 1 or its complement is considered a Toso gene. High stringency  
25 conditions are known in the art; see for example Maniatis, *et al.*, Molecular Cloning: A Laboratory Manual, 2d Edition (1989), and Short Protocols in Molecular Biology, ed.

Ausubel, *et al.*, both of which are hereby incorporated by reference. [An example of such conditions includes hybridization at about 65°C in about 5xSSPE and washing conditions of about 65°C in about 0.1x SSPE.

5 In another embodiment, less stringent hybridization conditions are used; for example, moderate or low stringency conditions may be used, as are known in the art; see Maniatis and Ausubel, *supra*. An example of such conditions includes hybridization at about 50 to 55°C in 5xSSPE and washing conditions of about 50°C in about 5xSSPE.

10 The Toso proteins and nucleic acids of the present invention are preferably recombinant. As used herein, "nucleic acid" may refer to either DNA or RNA, or molecules which contain both deoxy- and ribonucleotides. The nucleic acids include genomic DNA, cDNA and oligonucleotides including sense and anti-sense nucleic acids. Such nucleic acids may also contain modifications in the ribose-phosphate backbone to increase stability and half life of such molecules in physiological environments.

15 The nucleic acid may be double stranded, single stranded, or contain portions of both double stranded or single stranded sequence. As will be appreciated by those in the art, the depiction of a single strand ("Watson") also defines the sequence of the other strand ("Crick"); thus the sequence depicted in Figure 1 also includes the complement of the sequence. By the term "recombinant nucleic acid" herein is meant nucleic acid, originally formed *in vitro*, in general, by the manipulation of nucleic acid by endonucleases, in a form not normally found  
20 in nature. Thus an isolated Toso nucleic acid, in a linear form, or an expression vector formed *in vitro* by ligating DNA molecules that are not normally joined, are both considered recombinant for the purposes of this invention. It is understood that once a recombinant nucleic acid is made and reintroduced into a host cell or organism, it will replicate non-recombinantly, *i.e.* using the *in vivo* cellular machinery of the host cell rather than *in vitro*  
25 manipulations; however, such nucleic acids, once produced recombinantly, although subsequently replicated non-recombinantly, are still considered recombinant for the purposes of the invention.



Similarly, a "recombinant protein" is a protein made using recombinant techniques, *i.e.* through the expression of a recombinant nucleic acid as depicted above. A recombinant protein is distinguished from naturally occurring protein by at least one or more characteristics. For example, the protein may be isolated or purified away from some or all of the proteins and compounds with which it is normally associated in its wild type host, and thus may be substantially pure. For example, an isolated protein is unaccompanied by at least some of the material with which it is normally associated in its natural state, preferably constituting at least about 0.5%, more preferably at least about 5% by weight of the total protein in a given sample. A substantially pure protein comprises at least about 75% by weight of the total protein, with at least about 80% being preferred, and at least about 90% being particularly preferred. The definition includes the production of a Toso protein from one organism in a different organism or host cell. Alternatively, the protein may be made at a significantly higher concentration than is normally seen, through the use of a inducible promoter or high expression promoter, such that the protein is made at increased concentration levels. Alternatively, the protein may be in a form not normally found in nature, as in the addition of an epitope tag or amino acid substitutions, insertions and deletions, as discussed below.

Once identified, the polypeptides comprising the biologically active sequences may be prepared in accordance with conventional techniques, such as synthesis (for example, use of a Beckman Model 990 peptide synthesizer or other commercial synthesizer).

Also included within the definition of Toso proteins of the present invention are amino acid sequence variants. These variants fall into one or more of three classes: substitutional, insertional or deletional variants. These variants ordinarily are prepared by site specific mutagenesis of nucleotides in the DNA encoding the Toso protein, using cassette or PCR mutagenesis or other techniques well known in the art, to produce DNA encoding the variant, and thereafter expressing the DNA in recombinant cell culture as outlined above. However, variant Toso protein fragments having up to about 100-150 residues may be prepared by *in vitro* synthesis using established techniques. Amino acid sequence variants are characterized

by the predetermined nature of the variation, a feature that sets them apart from naturally occurring allelic or interspecies variation of the Toso protein amino acid sequence. The variants typically exhibit the same qualitative biological activity as the naturally occurring analogue, although variants can also be selected which have modified characteristics as will be more fully outlined below.

While the site or region for introducing an amino acid sequence variation is predetermined, the mutation per se need not be predetermined. For example, in order to optimize the performance of a mutation at a given site, random mutagenesis may be conducted at the target codon or region and the expressed Toso variants screened for the optimal combination of desired activity. Techniques for making substitution mutations at predetermined sites in DNA having a known sequence are well known, for example, M13 primer mutagenesis and PCR mutagenesis. Screening of the mutants is done using assays of Toso protein activities; for example, for binding domain mutations, competitive binding studies such as are outlined in the Examples may be done.

Amino acid substitutions are typically of single residues; insertions usually will be on the order of from about 1 to 20 amino acids, although considerably larger insertions may be tolerated. Deletions range from about 1 to about 20 residues, although in some cases deletions may be much larger. For example, a preferred variant comprises the deletion of the cytoplasmic domain, leaving only the extracellular domain of Toso, preferably including the transmembrane domain. Additional preferred variants comprise the cytoplasmic domain alone or a soluble receptor (*i.e.* the extracellular domain lacking the transmembrane domain).

Substitutions, deletions, insertions or any combination thereof may be used to arrive at a final derivative. Generally these changes are done on a few amino acids to minimize the alteration of the molecule. However, larger changes may be tolerated in certain circumstances. When small alterations in the characteristics of the Toso protein are desired, substitutions are generally made in accordance with the following chart:

-17-

Chart I

	<u>Original Residue</u>	<u>Exemplary Substitutions</u>
	Ala	Ser
	Arg	Lys
5	Asn	Gln, His
	Asp	Glu
	Cys	Ser
	Gln	Asn
	Glu	Asp
10	Gly	Pro
	His	Asn, Gln
	Ile	Leu, Val
	Leu	Ile, Val
	Lys	Arg, Gln, Glu
15	Met	Leu, Ile
	Phe	Met, Leu, Tyr
	Ser	Thr
	Thr	Ser
	Trp	Tyr
20	Tyr	Trp, Phe
	Val	Ile, Leu

Substantial changes in function or immunological identity are made by selecting substitutions that are less conservative than those shown in Chart I. For example, substitutions may be made which more significantly affect: the structure of the polypeptide backbone in the area of the alteration, for example the alpha-helical or beta-sheet structure; the charge or hydrophobicity of the molecule at the target site; or the bulk of the side chain. The substitutions which in general are expected to produce the greatest changes in the polypeptide's properties are those in which (a) a hydrophilic residue, *e.g.* seryl or threonyl, is substituted for (or by) a hydrophobic residue, *e.g.*, leucyl, isoleucyl, phenylalanyl, valyl or alanyl; (b) a cysteine or proline is substituted for (or by) any other residue; (c) a residue having an electropositive side chain, *e.g.*, lysyl, arginyl, or histidyl, is substituted for (or by) an electronegative residue, *e.g.*, glutamyl or aspartyl; or (d) a residue having a bulky side chain, *e.g.*, phenylalanine, is substituted for (or by) one not having a side chain, *e.g.*, glycine.

-18-

The variants typically exhibit the same qualitative biological activity and will elicit the same immune response as the naturally-occurring analogue, although variants also are selected to modify the characteristics of the Toso proteins as needed. Alternatively, the variant may be designed such that the biological activity of the Toso protein is altered. For example,  
5 glycosylation sites, and more particularly one or more O-linked or N-linked glycosylation sites may be altered or removed. Either or both of the transmembrane domains may be altered or removed, to make a soluble or secreted protein, *i.e.* the extracellular domain.

Covalent modifications of Toso polypeptides are included within the scope of this invention. One type of covalent modification includes reacting targeted amino acid residues of a Toso  
10 polypeptide with an organic derivatizing agent that is capable of reacting with selected side chains or the N-or C-terminal residues of a Toso polypeptide. Derivatization with bifunctional agents is useful, for instance, for crosslinking Toso to a water-insoluble support matrix or surface for use in the method for purifying anti-Toso antibodies or screening assays, as is more fully described below. Commonly used crosslinking agents include, *e.g.*, 1,1-  
15 bis(diazoacetyl)-2-phenylethane, glutaraldehyde, N-hydroxysuccinimide esters, for example, esters with 4-azidosalicylic acid, homobifunctional imidoesters, including disuccinimidyl esters such as 3,3'-dithiobis(succinimidylpropionate), bifunctional maleimides such as bis-N-maleimido-1,8-octane and agents such as methyl-3-[(p-azidophenyl)dithio]propioimide.

20 Other modifications include deamidation of glutaminyl and asparaginyl residues to the corresponding glutamyl and aspartyl residues, respectively, hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl or threonyl residues, methylation of the "- amino groups of lysine, arginine, and histidine side chains [T.E. Creighton, Proteins: Structure and Molecular Properties, W.H. Freeman & Co., San Francisco, pp. 79-86 (1983)],  
25 acetylation of the N-terminal amine, and amidation of any C-terminal carboxyl group.

Another type of covalent modification of the Toso polypeptide included within the scope of this invention comprises altering the native glycosylation pattern of the polypeptide.

"Altering the native glycosylation pattern" is intended for purposes herein to mean deleting

one or more carbohydrate moieties found in native sequence Toso polypeptide, and/or adding one or more glycosylation sites that are not present in the native sequence Toso polypeptide.

5 Addition of glycosylation sites to Toso polypeptides may be accomplished by altering the amino acid sequence thereof. The alteration may be made, for example, by the addition of, or substitution by, one or more serine or threonine residues to the native sequence Toso polypeptide (for O-linked glycosylation sites). The Toso amino acid sequence may optionally be altered through changes at the DNA level, particularly by mutating the DNA encoding the Toso polypeptide at preselected bases such that codons are generated that will  
10 translate into the desired amino acids.

Another means of increasing the number of carbohydrate moieties on the Toso polypeptide is by chemical or enzymatic coupling of glycosides to the polypeptide. Such methods are described in the art, *e.g.*, in WO 87/05330 published 11 September 1987, and in Aplin and Wriston, CRC Crit. Rev. Biochem., pp. 259-306 (1981).

15 Removal of carbohydrate moieties present on the Toso polypeptide may be accomplished chemically or enzymatically or by mutational substitution of codons encoding for amino acid residues that serve as targets for glycosylation. Chemical deglycosylation techniques are known in the art and described, for instance, by Hakimuddin, *et al.*, Arch. Biochem. Biophys., **259**:52 (1987) and by Edge, *et al.*, Anal. Biochem., **118**:131 (1981). Enzymatic  
20 cleavage of carbohydrate moieties on polypeptides can be achieved by the use of a variety of endo-and exo-glycosidases as described by Thotakura, *et al.*, Meth. Enzymol., **138**:350 (1987).

Another type of covalent modification of Toso comprises linking the Toso polypeptide to one of a variety of nonproteinaceous polymers, *e.g.*, polyethylene glycol, polypropylene glycol, or  
25 polyoxyalkylenes, in the manner set forth in U.S. Patent Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192; or 4,179,337.

Toso polypeptides of the present invention may also be modified in a way to form chimeric molecules comprising a Toso polypeptide fused to another, heterologous polypeptide or amino acid sequence. In one embodiment, such a chimeric molecule comprises a fusion of a Toso polypeptide with a tag polypeptide which provides an epitope to which an anti-tag antibody can selectively bind. The epitope tag is generally placed at the amino-or carboxyl-terminus of the Toso polypeptide. The presence of such epitope-tagged forms of a Toso polypeptide can be detected using an antibody against the tag polypeptide. Also, provision of the epitope tag enables the Toso polypeptide to be readily purified by affinity purification using an anti-tag antibody or another type of affinity matrix that binds to the epitope tag. In an alternative embodiment, the chimeric molecule may comprise a fusion of a Toso polypeptide with an immunoglobulin or a particular region of an immunoglobulin. For a bivalent form of the chimeric molecule, such a fusion could be to the Fc region of an IgG molecule or GST fusions.

Various tag polypeptides and their respective antibodies are well known in the art. Examples include poly-histidine (poly-his) or poly-histidine-glycine (poly-his-gly) tags; the flu HA tag polypeptide and its antibody 12CA5 [Field, *et al.*, Mol. Cell Biol., **8**:2159-2165 (1988)]; the c-myc tag and the 8F9, 3C7, 6E10, G4, B7, and 9E10 antibodies thereto [Evan, *et al.*, Molecular and Cellular Biology, **5**:3610-3616 (1985)]; and the Herpes Simplex virus glycoprotein D (gD) tag and its antibody [Paborsky, *et al.*, Protein Engineering, **3**(6):547-553 (1990)]. Other tag polypeptides include the Flag-peptide [Hopp, *et al.*, BioTechnology, **6**:1204-1210 (1988)]; the KT3 epitope peptide [Martin, *et al.*, Science, **255**:192-194 (1992)]; tubulin epitope peptide [Skinner, *et al.*, J. Biol. Chem., **266**:15163-15166 (1991)]; and the T7 gene 10 protein peptide tag [Lutz-Freyermuth, *et al.*, Proc. Natl. Acad. Sci. USA, **87**:6393-6397 (1990)].

Also included with the definition of Toso protein are other Toso proteins of the Toso family, and Toso proteins from other organisms, which are cloned and expressed as outlined below. Thus, probe or degenerate polymerase chain reaction (PCR) primer sequences may be used to find other related Toso proteins from humans or other organisms. As will be appreciated by

those in the art, particularly useful probe and/or PCR primer sequences include the unique areas of the Toso nucleic acid sequence. Thus, useful probe or primer sequences may be designed to: all or part of the sequence of the immunoglobulin V-like Toso domain, all or part of the unique extracellular domain, which spans roughly amino acids 18-253, or sequences outside the coding region. As is generally known in the art, preferred PCR primers are from about 15 to about 35 nucleotides in length, with from about 20 to about 30 being preferred, and may contain inosine as needed. The conditions for the PCR reaction are well known in the art.

Once the Toso nucleic acid is identified, it can be cloned and, if necessary, its constituent parts recombined to form the entire Toso nucleic acid. Once isolated from its natural source, *e.g.*, contained within a plasmid or other vector or excised therefrom as a linear nucleic acid segment, the recombinant Toso nucleic acid can be further-used as a probe to identify and isolate other Toso nucleic acids. It can also be used as a "precursor" nucleic acid to make modified or variant Toso nucleic acids and proteins.

Using the nucleic acids of the present invention which encode a Toso protein, a variety of expression vectors are made. The expression vectors may be either self-replicating extrachromosomal vectors or vectors which integrate into a host genome. Generally, these expression vectors include transcriptional and translational regulatory nucleic acid operably linked to the nucleic acid encoding the Toso protein. The term "control sequences" refers to DNA sequences necessary for the expression of an operably linked coding sequence in a particular host organism. The control sequences that are suitable for prokaryotes, for example, include a promoter, optionally an operator sequence, and a ribosome binding site. Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.

Nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence

if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, "operably linked" means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, the synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice. The transcriptional and translational regulatory nucleic acid will generally be appropriate to the host cell used to express the Toso protein; for example, transcriptional and translational regulatory nucleic acid sequences from *Bacillus* are preferably used to express the Toso protein in *Bacillus*. Numerous types of appropriate expression vectors, and suitable regulatory sequences are known in the art for a variety of host cells.

In general, the transcriptional and translational regulatory sequences may include, but are not limited to, promoter sequences, ribosomal binding sites, transcriptional start and stop sequences, translational start and stop sequences, and enhancer or activator sequences. In a preferred embodiment, the regulatory sequences include a promoter and transcriptional start and stop sequences.

Promoter sequences encode either constitutive or inducible promoters. The promoters may be either naturally occurring promoters or hybrid promoters. Hybrid promoters, which combine elements of more than one promoter, are also known in the art, and are useful in the present invention.

In addition, the expression vector may comprise additional elements. For example, the expression vector may have two replication systems, thus allowing it to be maintained in two organisms, for example in mammalian or insect cells for expression and in a procaryotic host for cloning and amplification. Furthermore, for integrating expression vectors, the expression vector contains at least one sequence homologous to the host cell genome, and preferably two homologous sequences which flank the expression construct. The integrating vector may be



directed to a specific locus in the host cell by selecting the appropriate homologous sequence for inclusion in the vector. Constructs for integrating vectors are well known in the art.

In addition, in a preferred embodiment, the expression vector contains a selectable marker gene to allow the selection of transformed host cells. Selection genes are well known in the art and will vary with the host cell used.

A preferred expression vector system is a retroviral vector system such as is generally described in PCT/US97/01019 and PCT/US97/01048, both of which are hereby expressly incorporated by reference.

The Toso proteins of the present invention are produced by culturing a host cell transformed with an expression vector containing nucleic acid encoding a Toso protein, under the appropriate conditions to induce or cause expression of the Toso protein. The conditions appropriate for Toso protein expression will vary with the choice of the expression vector and the host cell, and will be easily ascertained by one skilled in the art through routine experimentation. For example, the use of constitutive promoters in the expression vector will require optimizing the growth and proliferation of the host cell, while the use of an inducible promoter requires the appropriate growth conditions for induction. In addition, in some embodiments, the timing of the harvest is important. For example, the baculoviral systems used in insect cell expression are lytic viruses, and thus harvest time selection can be crucial for product yield.

Appropriate host cells include yeast, bacteria, archebacteria, fungi, and insect and animal cells, including mammalian cells, for example primary cells, including stem cells, including, but not limited to bone marrow stem cells. Of particular interest are *Drosophila melangaster* cells, *Saccharomyces cerevisiae* and other yeasts, *E. coli*, *Bacillus subtilis*, SF9 cells, C129 cells, 293 cells, Neurospora, BHK, CHO, COS, and HeLa cells, fibroblasts, Schwanoma cell lines, immortalized mammalian myeloid and lymphoid cell lines, Jukat cells, human cells and other primary cells.

In a preferred embodiment, the Toso proteins are expressed in mammalian cells. Mammalian expression systems are also known in the art, and include retroviral systems. A mammalian promoter is any DNA sequence capable of binding mammalian RNA polymerase and initiating the downstream (3') transcription of a coding sequence for Toso protein into mRNA. A promoter will have a transcription initiating region, which is usually placed proximal to the 5' end of the coding sequence, and a TATA box, using a located 25-30 base pairs upstream of the transcription initiation site. The TATA box is thought to direct RNA polymerase II to begin RNA synthesis at the correct site. A mammalian promoter will also contain an upstream promoter element (enhancer element), typically located within 100 to 200 base pairs upstream of the TATA box. An upstream promoter element determines the rate at which transcription is initiated and can act in either orientation. Of particular use as mammalian promoters are the promoters from mammalian viral genes, since the viral genes are often highly expressed and have a broad host range. Examples include the SV40 early promoter, mouse mammary tumor virus LTR promoter, adenovirus major late promoter, herpes simplex virus promoter, the CMV promoter, a retroviral LTR promoter, mouse maloney leukemia virus LTR, or pBabeMN.

Typically, transcription termination and polyadenylation sequences recognized by mammalian cells are regulatory regions located 3' to the translation stop codon and thus, together with the promoter elements, flank the coding sequence. The 3' terminus of the mature mRNA is formed by site-specific post-translational cleavage and polyadenylation. Examples of transcription terminator and polyadenylation signals include those derived from SV40.

The methods of introducing exogenous nucleic acid into mammalian hosts, as well as other hosts, is well known in the art, and will vary with the host cell used. Techniques include dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, protoplast fusion, electroporation, viral infection, encapsulation of the polynucleotide(s) in liposomes, and direct microinjection of the DNA into nuclei.

-25-

In a preferred embodiment, Toso proteins are expressed in bacterial systems. Bacterial expression systems are well known in the art.

A suitable bacterial promoter is any nucleic acid sequence capable of binding bacterial RNA polymerase and initiating the downstream (3') transcription of the coding sequence of Toso protein into mRNA. A bacterial promoter has a transcription initiation region which is usually placed proximal to the 5' end of the coding sequence. This transcription initiation region typically includes an RNA polymerase binding site and a transcription initiation site. Sequences encoding metabolic pathway enzymes provide particularly useful promoter sequences. Examples include promoter sequences derived from sugar metabolizing enzymes, such as galactose, lactose and maltose, and sequences derived from biosynthetic enzymes such as tryptophan. Promoters from bacteriophage may also be used and are known in the art. In addition, synthetic promoters and hybrid promoters are also useful; for example, the *tac* promoter is a hybrid of the *trp* and *lac* promoter sequences. Furthermore, a bacterial promoter can include naturally occurring promoters of non-bacterial origin that have the ability to bind bacterial RNA polymerase and initiate transcription.

In addition to a functioning promoter sequence, an efficient ribosome binding site is desirable. In *E. coli*, the ribosome binding site is called the Shine-Delgarno (SD) sequence and includes an initiation codon and a sequence 3-9 nucleotides in length located 3 - 11 nucleotides upstream of the initiation codon.

The expression vector may also include a signal peptide sequence that provides for secretion of the Toso protein in bacteria. The signal sequence typically encodes a signal peptide comprised of hydrophobic amino acids which direct the secretion of the protein from the cell, as is well known in the art. The protein is either secreted into the growth media (gram-positive bacteria) or into the periplasmic space, located between the inner and outer membrane of the cell (gram-negative bacteria).

-26-

The bacterial expression vector may also include a selectable marker gene to allow for the selection of bacterial strains that have been transformed. Suitable selection genes include genes which render the bacteria resistant to drugs such as ampicillin, chloramphenicol, erythromycin, kanamycin, neomycin and tetracycline. Selectable markers also include biosynthetic genes, such as those in the histidine, tryptophan and leucine biosynthetic pathways.

These components are assembled into expression vectors. Expression vectors for bacteria are well known in the art, and include vectors for *Bacillus subtilis*, *E. coli*, *Streptococcus cremoris*, and *Streptococcus lividans*, among others.

The bacterial expression vectors are transformed into bacterial host cells using techniques well known in the art, such as calcium chloride treatment, electroporation, and others.

In one embodiment, Toso proteins are produced in insect cells. Expression vectors for the transformation of insect cells, and in particular, baculovirus-based expression vectors, are well known in the art.

In a preferred embodiment, Toso protein is produced in yeast cells. Yeast expression systems are well known in the art, and include expression vectors for *Saccharomyces cerevisiae*, *Candida albicans* and *C. maltosa*, *Hansenula polymorpha*, *Kluyveromyces fragilis* and *K. lactis*, *Pichia guillermondii* and *P. pastoris*, *Schizosaccharomyces pombe*, and *Yarrowia lipolytica*. Preferred promoter sequences for expression in yeast include the inducible GAL1,10 promoter, the promoters from alcohol dehydrogenase, enolase, glucokinase, glucose-6-phosphate isomerase, glyceraldehyde-3-phosphate-dehydrogenase, hexokinase, phosphofructokinase, 3-phosphoglycerate mutase, pyruvate kinase, and the acid phosphatase gene. Yeast selectable markers include ADE2, HIS4, LEU2, TRP1, and ALG7, which confers resistance to tunicamycin; the neomycin phosphotransferase gene, which confers resistance to G418; and the CUP1 gene, which allows yeast to grow in the presence of copper ions.

-27-

The Toso protein may also be made as a fusion protein, using techniques well known in the art. Thus, for example, for the creation of monoclonal antibodies, if the desired epitope is small, the Toso protein may be fused to a carrier protein to form an immunogen.

Alternatively, the Toso protein may be made as a fusion protein to increase expression, or for other reasons. For example, when the Toso protein is a Toso peptide, the nucleic acid encoding the peptide may be linked to other nucleic acid for expression purposes.

In one embodiment, the Toso nucleic acids, proteins and antibodies of the invention are labeled. By "labeled" herein is meant that a compound has at least one element, isotope or chemical compound attached to enable the detection of the compound. In general, labels fall into three classes: a) isotopic labels, which may be radioactive or heavy isotopes; b) immune labels, which may be antibodies or antigens; and c) colored or fluorescent dyes. The labels may be incorporated into the compound at any position.

In a preferred embodiment, the Toso protein is purified or isolated after expression. Toso proteins may be isolated or purified in a variety of ways known to those skilled in the art depending on what other components are present in the sample. Standard purification methods include electrophoretic, molecular, immunological and chromatographic techniques, including ion exchange, hydrophobic, affinity, and reverse-phase HPLC chromatography, and chromatofocusing. For example, the Toso protein may be purified using a standard anti-Toso antibody column. Ultrafiltration and diafiltration techniques, in conjunction with protein concentration, are also useful. For general guidance in suitable purification techniques, see Scopes, R., Protein Purification, Springer-Verlag, NY (1982). The degree of purification necessary will vary depending on the use of the Toso protein. In some instances no purification will be necessary.

Once expressed and purified if necessary, the Toso proteins and nucleic acids are useful in a number of applications.

-28-

In a preferred embodiment, modified Toso cell-surface receptors, and cells containing the modified receptors, are made. In one embodiment, non-human animals (preferably transgenic) are made that contain modified Toso receptors; similarly, "knock-out" animal models and Toso transgenic animals that may contain an inducible promoter may be made. In addition, cells, particularly mammalian, can be made comprising a modified Toso cell surface receptor.

In one embodiment, the Toso proteins of the present invention may be used to generate polyclonal and monoclonal antibodies to the full length protein, the extracellular or cytoplasmic domains of Toso proteins, which are useful as described herein. Similarly, the Toso proteins can be coupled, using standard technology, to affinity chromatography columns. These columns may then be used to purify Toso antibodies. In a preferred embodiment, the antibodies are generated to epitopes unique to the Toso protein; that is, the antibodies show little or no cross-reactivity to other proteins. These antibodies find use in a number of applications. For example, the Toso antibodies may be coupled to standard affinity chromatography columns and used to purify Toso proteins. The antibodies may also be used as described below.

In a preferred embodiment, antibodies, particularly monoclonal antibodies, are used to modulate the biological function of a Toso protein. "Modulating the activity of Toso" includes an increase in activity, a decrease in activity, or a change in the type or kind of activity present. By "Toso activity" or grammatical equivalents herein is meant the ability of Toso after activation to modulate apoptosis. As outlined herein, upon T cell activation, Toso is activated, initiating a signalling pathway that results in modulation of apoptosis. Such modulation may result in response to either of the extracellular or cytoplasmic domains of Toso and may correspond to a decrease or an increase in apoptosis. In a preferred embodiment, the activity of Toso (either or both of the extracellular or cytoplasmic domain of Toso) is increased; in another preferred embodiment, the activity of Toso is decreased.

In a preferred embodiment, methods of modulating apoptosis in a cell are provided, comprising administering to the cell a recombinant nucleic acid encoding a Toso protein, or a Toso protein. This includes treating an apoptosis related condition or apoptosis mediated disorders, which include, but are not limited to, any disease characterized by T cell  
5 overactivity, including, but not limited to Sjogrens mixed connective tissue disease, autoimmune disorders including, but not limited to, lupus (SLE), rheumatoid arthritis (RA), multiple sclerosis, and autoimmune diseases which are tissue specific, for example liver (hepatitis), kidney (nephritis) or Hashimoto (thyroiditis); diseases where T cells actively destroy cells, for example, cytotoxic effects including, but not limited to, transplant rejection,  
10 disease conditions based on graft vs. host or host vs. graft reactions; conditions where cells of any kind that are not dying express Toso appropriately, for example, cancer of T or B cell origin (where increased apoptosis would be desirable), including but not limited to, leukemias and lymphomas, Chrohn's disease, skin inflammatory disorders (psoriasis, eczema); and diseases secondary to altered immunoglobulin production such as Waldenstroms, and  
15 multiple myeloma.

In one embodiment, a therapeutically effective dose of a Toso is administered to a patient. This may be done either by the administration of a Toso protein, or a nucleic acid encoding a Toso protein, as is known in the art. By "therapeutically effective dose" herein is meant a dose that produces the effects for which it is administered. The exact dose will depend on the  
20 purpose of the treatment, and will be ascertainable by one skilled in the art using known techniques. As is known in the art, adjustments for Toso degradation, systemic versus localized delivery, and rate of new protease synthesis, as well as the age, body weight, general health, sex, diet, time of administration, drug interaction and the severity of the condition may be necessary, and will be ascertainable with routine experimentation by those  
25 skilled in the art.

A "patient" for the purposes of the present invention includes both humans and other animals, particularly mammals, and organisms. Thus the methods are applicable to both human

therapy and veterinary applications. In the preferred embodiment the patient is a mammal, and in the most preferred embodiment the patient is human.

The administration of the Toso proteins of the present invention can be done in a variety of ways, including, but not limited to, orally, subcutaneously, intravenously, intranasally, 5 transdermally, intraperitoneally, intramuscularly, intrapulmonary, vaginally, rectally, or intraocularly. In some instances, for example, in the treatment of wounds and inflammation, the Toso may be directly applied as a solution or spray.

The pharmaceutical compositions of the present invention comprise a Toso protein in a form suitable for administration to a patient. In the preferred embodiment, the pharmaceutical 10 compositions are in a water soluble form, such as being present as pharmaceutically acceptable salts, which is meant to include both acid and base addition salts.

"Pharmaceutically acceptable acid addition salt" refers to those salts that retain the biological effectiveness of the free bases and that are not biologically or otherwise undesirable, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, 15 phosphoric acid and the like, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like. "Pharmaceutically acceptable base addition salts" include those derived from inorganic bases such as sodium, 20 potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Particularly preferred are the ammonium, potassium, sodium, calcium, and magnesium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange 25 resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine.



The pharmaceutical compositions may also include one or more of the following: carrier proteins such as serum albumin; buffers; fillers such as microcrystalline cellulose, lactose, corn and other starches; binding agents; sweeteners and other flavoring agents; coloring agents; and polyethylene glycol. Additives are well known in the art, and are used in a variety of formulations.

The following examples serve to more fully describe the manner of using the above-described invention, as well as to set forth the best modes contemplated for carrying out various aspects of the invention. It is understood that these examples in no way serve to limit the true scope of this invention, but rather are presented for illustrative purposes. All references cited herein are incorporated by reference.

#### EXAMPLE I

##### **Molecular Cloning and Chromosomal Localization of Toso.**

Jurkat cells (human T cell line, a gift of Dr. Calvin Kuo, Harvard Univ.) were infected with a retroviral Jurkat T cell cDNA library to screen for cDNAs that encode inhibitory molecules for Fas-induced apoptosis. A retroviral library containing  $2 \times 10^6$  independent cDNA inserts was constructed from Jurkat cell mRNA by standard methods (Kinoshita and Nolan, unpublished) using a retrovirus vector pBabeMN (Kinoshita, *et al.* (1997)). The library was transfected into an ecotropic virus packaging cell line,  $\phi$ NX-Ampho, as described previously. Jurkat cells were spin-infected with the supernatant from  $\phi$ NX-A cells resulting in 20-40% infection using this method as determined by doping of the library with a marker retrovirus pBabeMN-LacZ or pBabeMN-Lyt-2- $\alpha$  (194 amino acids), which does not have cytoplasmic domain (Tagawa, *et al.*, Proc. Natl. Acad. Sci., **83**:3422-3426 (1986)). Jurkat cells were aliquoted into 96-well plates in media containing 10 ng/ml of anti-human Fas mAb, CH11, (Kamiya Biomedical Company, CA 91359, U.S.A.) for 15 days. Jurkat cells, under conditions empirically derived, were sensitive to Fas-mediated apoptosis with a spontaneous survival rate under our conditions of 2-3 per  $10^6$  cells. Cells that survived the Fas-mediated killing were identified by outgrowth in the 96 well plate format, expanded, total RNA extracted, and cDNA inserts rescued using RT-PCR (AMV reverse transcriptase from

-32-

Promega, W1 53711, U.S.A. and Vent DNA polymerase from New England Biolabs, Inc., MA 01915, U.S.A.) with primers 5'-GCT CAC TTA CAG GCT CTC TA (LibS) and 5'-CAG GTG GGG TCT TTC ATT CC (LibA), which were located 282 bp and 56 bp nucleotides upstream and downstream of cDNA insert cloning sites. After an initial denaturation at 94°C for 5 minutes, each cycle of amplification consisted of 30 second denaturation at 94°C, followed by a 30 second-annealing at 58°C and 2 minutes extension at 72°C. After 35 cycles, the final product was extended for 10 minutes at 72°C. The rescued inserts were digested with BamHI-Sall (Promega) or BstXI (Promega), and ligated into the pBabeMN retrovirus vector. The cloned retrovirus containing the novel insert was infected into Jurkat cells. Cells were cultured with 10 ng/ml anti-Fas mAb to confirm whether the inhibitory effect was caused by cDNA inserts of retrovirus. 26 clones were obtained that were resistant to Fas-induced apoptosis, of which 12 carried cDNA inserts. After a second round of anti-Fas screening, one clone, termed here Toso, demonstrated potent inhibition of Fas-induced apoptotic signaling.

The cDNA insert of Toso was found to contain a 5'-non-coding region of 73 nucleotides, a coding region of 1173 nucleotides (390 amino acids) and a 3'-non-coding region of 665 nucleotides. (See Figure 1, SEQ ID NO:1). The ATG initiation codon is contained within a standard Kozak consensus sequence. Kyte-Doolittle hydropathy plot analysis showed that Toso has two hydrophobic regions: the amino-terminal residues from 1 to 17 correspond to the deduced signal sequence (underlined) and residues from 254 to 272 (double underlined) correspond to a presumptive transmembrane region [Hofmann and Stoffel, 1993, analysis was performed using DNAsis-Mac V2.0 (Hitachi Software Engineering, Co. Ltd., Japan)], suggesting that Toso is a type I integral membrane protein. (See Figure 2b). The predicted molecular weight of Toso is 41 kDa. The cytoplasmic region of Toso has a basic amino acid-rich region (from R<sup>274</sup> to R<sup>323</sup>), a proline-rich region (from P<sup>334</sup> to P<sup>346</sup>), and an acidic amino acid-rich region (from E<sup>378</sup> to D<sup>384</sup>) (See Figure 2a and 2b, SEQ ID NO: 2). BLAST search analysis revealed that Toso is a unique gene (Altschul, *et al.*, (1990)). The extracellular domain of Toso has homology to the immunoglobulin variable (IgV) domains, which is characterized by motifs in the  $\beta$ -strand B, D and F regions, (residues VTLTC, RV(or

F, I) and DSG(or A)-Y-CA ) (Williams and Barclay, Ann. Rev. Immunol., 6:381-405 (1988)). Importantly, the cysteines in the IgV-like motif VTIKC at position 33 in Toso, as well as the cysteine in the IgV-like motif DSGVYAC at position 98, are appropriately distanced as in other IgV-like domains to form a disulphide bond. Toso also contains within the Ig domains two additional cysteines that are not conserved in other IgV-like domains. Thus, the presumptive extracellular domain has all the requisite features that demarcate it as a potential IgV-like domain. The cytoplasmic region of Toso has partial homology to FAST kinase, acid sphingomyelinase, insulin receptor substrate-1 (IRS-1) and the apoptosis inhibitor from *Orgyia pseudotsugata* nuclear polyhedrosis virus (Op-IAP) (Figure 3), which might function to initiate some of the signaling systems acted upon by Toso.

The Toso gene was mapped to a human chromosome by using a panel of 17 human X Chinese hamster hybrid cell lines derived from several independent fusion experiments (Francke et al., 1986). PCR primers used to amplify Toso sequence derived from the 3' untranslated region were 5'-AGA GGC ATA GCT ATT GTC TCG G (sense; located 369 bp downstream of the coding region), and 5'-ACA TTT GGA TCA GGG CAA AG (anti-sense; 508 bp downstream of the coding region). The size of the PCR product was 159 bp. The PCR conditions were 94°C, 90 seconds; then 35 cycles of 94°C, 20 seconds; 55°C, 30 seconds; 72°C, 45 seconds; followed by 72°C, 5 minutes. Specific PCR products were obtained from human genomic DNA, and hybrid cell lines that carry human chromosome 1. The PCR product was sequenced to confirm its identity.

To map the Toso gene locus more precisely, two human radiation hybrid (RH) mapping panels were typed by PCR. GeneBridge 4 (Whitehead Institute/MIT Genome Center) and Stanford G3 (Stanford Human Genome Center), were obtained from Research Genetics, Inc. (Cox, *et al.*, Science, 250:245-250 (1990); Walter, *et al.*, Net Genet., 7:22-28 (1994)), and samples were typed using the primers and PCR conditions described above. Results of the maximum likelihood analysis (Boehnke, *et al.*, Am. J. Hum. Genet., 49:1174-1188 (1991)) were obtained by submitting the raw scores to:

<http://www-genome.wi.mit.edu/cgibin/contig/rhmapper.pl> and

[http://www.shgc.stanford.edu/rhserver2/rhserver\\_form.html](http://www.shgc.stanford.edu/rhserver2/rhserver_form.html). The cytological localization of the Toso gene was deduced from the cytogenetic information about the flanking markers in Bray-Ward et al (Bray-Ward, *et al.*, Genomics, **32**:1-14 (1996)). In the Stanford G3 mapping panel, Toso cosegregated with chromosome 1 marker D1S3553 on all 83 Stanford G3 panel RH cell lines. D1 S3553 is a known marker of chromosome 1 bin 115 on the SHGC RH map. In the GeneBridge 4 mapping panel, Toso is located 5.4 cR<sub>3000</sub> and 1.7 cR<sub>3000</sub> from D1 S504 and W1-9641, respectively. The order of loci in this region from centromere to qter is: D1S412 - D1S306 D1S504 - Toso - W1-9641 - D1S491 - D1S237. According to Bray-Ward et al. (1996), the YACs containing the more proximal markers D1S412 (bin 104), D1S477 (bin 109) and D1S504 (bin 114) were mapped to 1q25-q32, 1q31-q32 and 1q25-q32 respectively, and the YACs containing the more distal markers D1 S491 (bin 118), D1 S414 (bin 121) and D1 S237 (bin 124) were mapped to essentially the same region, 1q31-q32, 1q31-q32 and 1q32-q41, respectively. Thus, the Toso gene is located at 1q31-q32, a region in which several chromosomal abnormalities relating to leukemias are localized.

Toso is a negative regulator of Fas-mediated cell death in lymphoid cells, and may therefore be involved in oncogenic events or resistance to chemotherapy (Friesen, *et al.*, Nature Medicine, **2**:574-577 (1996)). The gene for Toso localizes within human chromosome region 1q31-q32. Chromosomal changes in 1q32 are frequently observed in human cancer, including various types of hematopoietic malignancies and solid tumors (Jinnai, *et al.*, Am. J. Hematol, **35**:118-124 (1990); Mertens, *et al.*, Cancer Res., **57**:2765-2780 (1997); Mitelman, *et al.*, Nat. Genet., 417-474 (1997); Schmid and Kohler, Cancer Genet. Cytogenet., **11**:121-23 (1984); Shah, *et al.*, Cancer Genet. Cytogenet., **61**:183-192 (1992); Waghray, *et al.*, Cancer Genet. Cytogenet., **23**:225-237 (1986); Yip, *et al.*, Cancer Genet. Cytogenet., **51**:235-238 (1991)). Furthermore, studies in nude mice demonstrated that duplication of the chromosome segment of 1 q11 -q32 is associated with proliferation and metastasis of human chronic lymphocytic leukemic B-cells (Ghose, *et al.*, Cancer Res., **50**:3737-3742 (1990)), suggesting the presence of dominantly acting growth regulatory or cell survival genes. Thus, Toso is a candidate for evaluation as a proto-oncogene in several proliferative and metastatic neoplasms.

## EXAMPLE 2

### Toso Inhibits Fas-, TNF $\alpha$ - and FADD-Induced Apoptosis.

Jurkat cells that express the receptor for ecotropic murine retroviruses ("Jurkat.ecoR") were infected with retroviruses that express Toso and control vectors, pBabeMN-Toso, pBabeMN-lacZ and pBabeMN-Lyt-2- $\alpha'$  ( $\alpha'$  form of mouse CD8 $\alpha$  chain) (Tagawa, *et al.* (1986)). Cells were cultured in the presence of several reagents such as anti-Fas mAb (Kamiya Biomedical Company), staurosporine (SIGMA Chemical Company, MO 63178, U.S.A.), ceramide (SIGMA), PMA (SIGMA)/Ionomycin (SIGMA), human TNF- $\alpha$  (R&D systems, Minneapolis, MN 55413)/Cycloheximide (SIGMA). After 12 or 24 hours, the cells were stained with 100  $\mu$ g/ml ethidium bromide (SIGMA) and 100  $\mu$ g/ml acridine orange (SIGMA). Apoptotic cells and non-apoptotic cells were identified with UV microscopy as described (MacGahon, *et al.*, *The End of the (Cell) Line: Methods for the Study of Apoptosis in vitro*, in *Methods in cell biology*, L.J. Schwartz and B.A. Osborne, eds., San Diego, California, Academic Press, Inc., pp. 172-173 (1995)). For FADD-induced apoptosis, mouse FADD (a gift from Dr. Angeles Estelles, Dept. Mol. Pharm., Stanford Univ.) was ligated into pBabeMN retroviral vector. Jurkat.ecoR cells expressing Lyt-2- $\alpha'$  or Toso were infected with pBabeMN-LacZ or pBabeMN-FADD. After 24 hours infection with FADD, the cells were stained with ethidium bromide and acridine orange and counted the apoptotic cells. Jurkat.ecoR cells were infected with pBabeMN-lacZ, pBabeMN-Lyt-2- $\alpha'$ , and pBabeMN-Toso. At 72 hours postinfection, infection frequency of pBabeMN-lacZ and pBabeMN-Lyt-2 $\alpha'$  were determined to be 45% and 58%, respectively. Jurkat cells were then cultured with 10 ng/ml anti-Fas mAb for 24 hours and apoptotic cells were counted. Jurkat.ecoR cells expressing Toso were resistant to apoptosis induced by 10 ng/ml of anti-Fas mAb, whereas Jurkat cells, Jurkat.ecoR cells and Jurkat.ecoR cells that expressed lacZ or Lyt-2- $\alpha'$ , all succumbed to apoptotic death (Figure 4a).

Staurosporine is a bacterial alkaloid that is a broad spectrum inhibitor of protein kinases (Tamaoki and Nakano, *Biotechnology*, **8**:732-735 (1990)) and induces programmed cell death in various cell lines and dissociated primary cells in culture (Ishizaki, *et al.*, *J. Cell Biol.*, **121**:899-908 (1993); Jacobson, *et al.*, *Nature*, **361**:365-369 (1993); Raff, *et al.*, *Science*,

262:695-700 (1993)). Ceramide generation is implicated in a signal transduction pathway that mediates programmed cell death induced by Fas and TNF- $\alpha$  (Cifone, *et al.*, J. Exp. Med., **180**:1547-1552 (1994); Obeid, *et al.*, Science, **259**:1769-1771 (1993)). pBabeMN-LacZ infected cells were counted by microscopic observation; infection frequency was determined to be 57%. At 72 hours postinfection, Jurkat.ecoR cells and Jurkat.ecoR cells infected with pBabeMN-lacZ and pBabeMN-Toso were cultured with anti-Fas mAb, staurosporine and ceramide for 24 hours. Although Jurkat.ecoR cells expressing Toso were resistant to Fas-mediated apoptosis over a range of antiFas dilutions, these cells were not resistant to any concentration of staurosporine- or ceramide-induced apoptosis (Figure 4b).

The Fas receptor has homology to the TNF- $\alpha$  receptor, and these two receptors share analogous signaling systems as well as several intracellular mediators (Hsu, *et al.*, Cell, **84**:299-308 (1996)). The protective effect of Toso against TNF- $\alpha$ -induced apoptosis was tested by culturing Jurkat.ecoR cells expressing Lyt-2- $\alpha'$  or Toso with 10 ng/ml of anti-Fas mAb or 1  $\mu$ g/ml of TNF- $\alpha$  in the presence of 0.1  $\mu$ g/ml of cyclohexamide (CHX) for 12 hours and apoptotic cells were counted. The infection frequency of pBabeMN-Lyt-2- $\alpha'$  was determined to be 58%. Toso inhibited Fas induced apoptosis in the presence of CHX and also protected against TNF- $\alpha$ -induced apoptosis in comparison to Jurkat.ecoR expressing Lyt-2- $\alpha'$  (Figure 4d). Thus the TNF- $\alpha$  and Fas signaling pathways may converge at a common point that can be inhibited by Toso.

**Fas-mediated apoptosis is activated through FADD.** The effect of Toso on FADD-induced apoptosis was investigated by infecting Jurkat.ecoR cells expressing Lyt-2- $\alpha'$  or Toso, with pBabeMN-LacZ or pBabeMN-FADD. The reinfection efficiency was approximately 40% using pBabeMN-LacZ. Jurkat.ecoR cells were infected with pBabeMN-Lyt-2- $\alpha'$ , and pBabeMN-Toso. Infection frequency of pBabeMN-Lyt-2- $\alpha'$  was determined to be 72%. Jurkat.ecoR cells expressing Lyt-2- $\alpha'$  or Toso were infected with pBabeMNLacZ or pBabeMN-FADD and apoptotic cells were counted at 24 hours postinfection. Infection frequency of pBabeMN-lacZ in Jurkat.ecoR cells expressing Lyt-2- $\alpha'$  and Toso was determined to be 39% and 43%, respectively. As shown in Figure 4c, FADD

induced apoptosis in 45% of control Jurkat cells. However, FADD failed to induce apoptosis in Jurkat.ecoR cells constitutively expressing Toso.

The downstream effects of Toso on known inhibitors of apoptosis, were evaluated by western blot analysis of Bcl-2 and Bcl-XL expression levels in Toso expressing cells. For detection of Toso or deletion mutants that has a HA tag, whole-cell lysates ( $2 \times 10^5$  cells per lane) were resolved by SDS-PAGE, transferred to an Immobilon-P transfer membrane (Millipore, Bedford, MA 01730, U.S.A.) and processed using ECL western blotting analysis system (Amersham Life Science, Arlington Heights, IL 60005, U.S.A.) with Mouse monoclonal anti-hemagglutinin antibody (HA.11) (Babco, Richmond, CA 94804, U.S.A.) as per manufacturer recommendation. Bcl-2 overexpression can block Fas-induced apoptosis as well as staurosporine-induced apoptosis (data not shown). No change in the levels of expression of Bcl-2 or Bcl-XL was observed by Western blot (data not shown). Thus, it appears that intracellular signaling events generated by FADD can be directly and efficiently blocked by signals emanating from Toso at a point prior to engagement of Bcl-2 and Bcl-XL. The results also suggest that Toso's effect is not due to down regulation of FADD gene expression.

The effect of overexpression of Toso on processing of caspase-8, which associates with FADD, was evaluated. The processed form (p20) of FLICK after Fas activation was greatly reduced in pBabeMN-Toso-infected Jurkat.ecoR cells in comparison with control Jurkat.ecoR cells (see Figure 5a). To detect caspase-8, whole-cell lysates ( $2 \times 10^6$  cells per lane) were resolved by SDS-PAGE, transferred to an membrane and processed with goat anti-Mch5 p20 antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA 95060, U.S.A.) as described above. This data indicates that Toso inhibits caspase-8 processing after Fas activation. cFLIP expression was induced by Toso (Figure 5b). These results strongly suggest that the extracellular domain of Toso inhibits Fas-induced apoptosis by preventing caspase-8 processing through cFLIP upregulation. Toso did not inhibit staurosporine-induced programmed cell death and staurosporine has been shown to activate caspase-8 (Jacobsen, *et al.*, J. Cell Biol., **133**:1041-1051 (1996)). Therefore, additional Toso effects do not occur

downstream, nor at the level, of caspase-8. Supporting this, Toso also did not inhibit ceramide-induced apoptosis, which acts downstream or independent of caspase-8 as demonstrated in experiments using the caspase-8-specific inhibitor peptide, DEVD-CHO (Gamen, *et al.*, FEBS Lett., **390**:232-237 (1996)), which does not inhibit ceramide-induced apoptosis. Overexpression of Bcl-2 or Bcl-XL is known to prevent apoptosis in response to ceramide and staurosporine (Geley, *et al.*, FEBS Lett., **400**:15-18 (1997); Susin, *et al.*, J. Exp. Med., **186**:25-37 (1997); Takayama, *et al.*, Cell, **80**:279-284 (1995); Zhang, *et al.*, Proc. Natl. Acad. Sci. USA, **93**:5325-5328 (1996)). Toso did not change the expression levels of Bcl-2 nor BCL-XL in Jurkat cells, showing that neither Bcl-2 nor BCL-XL were involved in the protective activities of Toso. Taken together then, Toso activates an inhibitory pathway that prevents caspase-8 activation following Fas stimulation through upregulation of cFLIP, and not by blocking apoptotic signals downstream or at the level of caspase-8. This explains the apparent specificity of the blockade to TNF family-related surface receptors that use caspase-8 for apoptotic signaling.

Cells expressing Toso alone were mixed with an equal number of cells expressing lacZ. After one round of Fas stimulation, no lacZ-expressing cells remained as assayed by X-gal. In addition, Jurkat.ecoR cells were infected with pBabeMN-Toso-IRES-GFP. After infection, cells were cultured with ( $\alpha$ -Fas (+)) or without ( $\alpha$ -Fas (-)) 50 ng/ml of anti-Fas mAb. In the absence of anti-Fas mAb treatment (Fas (-)), 46% GFP negative cells and 54% GFP positive cells were observed in pBabeMN-Toso-IRES-GFP-infected Jurkat.ecoR cells. After five days culture with anti-Fas mAb, survivors were obtained from pBabeMN-Toso-IRES-GFP-infected Jurkat.ecoR cells, but not from control pBabeMN-IRES-GFP-infected Jurkat.ecoR cells (data not shown); 99.7 % of surviving Jurkat cells expressed GFP as shown in Figure 4e (Fas(+)). These data indicate that cells that express the extracellular domain of Toso are protected from Fas-induced apoptosis and suggests that Toso does not exert its effect as a secreted form.

### EXAMPLE 3



**The Immunoglobulin Domain and the Transmembrane Region of Toso Are Required for Inhibition of Fas-induced Apoptosis.**

The C-terminus deletion mutants (Toso $\Delta$ (377-390).HA, Toso $\Delta$ (334-390).HA, Toso $\Delta$ (281-390).HA and Toso $\Delta$ (252-390).HA), the N-terminus deletion mutant (Toso $\Delta$ (29-187).HA) and the fusion protein (Lyt-2/Toso(271-390).HA) of the extracellular domain and transmembrane region from Lyt-2- $\alpha'$  and the cytoplasmic domain from Toso, which have the influenza virus hemmagglutinin tag (HA) in C-terminus, were generated by. Primers in the antisense orientation, carrying the 20 nucleotide sequences of Toso located upstream of the deletion sites, HA tag sequence and an in-frame termination codon, as well as NcoI site, were synthesized. The DNA fragment of the Toso gene from the XhoI site located in the extracellular domain to the NcoI site that is located in 3' non-coding region was replaced with the PCR products amplified from pBabeMN-Toso using LibS and each primer described above. A primer for Toso $\Delta$ (29-187).HA in the antisense orientation carrying the 20 nucleotides located after the leader peptides of Toso and XhoI site was synthesized. The DNA fragment from Dralil site, which is located 190 bp upstream of cDNA insert cloning sites, to XhoI site in pBabeMN-Toso.HA was replaced with the PCR product amplified from pBabeMN-Toso using LibS and the primer. For Lyt2/Toso(271-390).HA, primer in sense orientation which is carried a BamHI site and the 20 nucleotides located upstream of the cytoplasmic domain was synthesized. The DNA fragment from Bcl I site, which is located in the end of transmembrane region of Lyt-2- $\alpha'$ , to Sall site, which is located downstream of Lyt-2- $\alpha'$  cloning sites in pBabeMN-Lyt-2- $\alpha'$ , was replaced with the PCR product amplified from pBabeMN-Toso.HA using LibA and the primer. All mutants generated by PCR were verified by DNA sequencing using cycle sequencing ready reaction kit. Toso deletion mutants prepared as described above were epitope-tagged in order to delineate the regions responsible for anti-apoptotic signal transduction, (Figures 6a and 6b). Toso.HA (fused to the hemagglutinin, HA, tag) had an apparent molecular weight of 60 kDa, suggesting Toso is heavily glycosylated. The cell surface expression of Fas using anti-human Fas mAb, CH11, was determined by FACS to explore whether Toso has an effect on Fas expression. Fas was expressed at similar levels on the surface of cells expressing either full-length Toso, Toso

deletion mutants, or control vector. Thus, the extracellular domain of Toso neither downregulates Fas, nor directly interferes with the ability of the antibody to bind and presumably stimulate Fas.

Jurkat.ecoR cells were infected with pBabeMN-Lyt-2- $\alpha'$ .HA, pBabeMN-Toso.HA, pBabeMN-Toso $\Delta$ (377-390).HA, pBabeMN-Toso $\Delta$ (334-390).HA, pBabeMN-Toso $\Delta$ (281-390).HA, pBabeMNToso $\Delta$ (252-390).HA and pBabeMN-Toso $\Delta$ (29-187).HA. Jurkat cells were cultured with 10 ng/ml anti-Fas mAb for 24 hours and apoptotic cells were counted. Apoptosis was readily induced in control Jurkat.ecoR cells and Jurkat.ecoR cells expressing Lyt-2- $\alpha'$ .HA, whereas apoptosis was markedly inhibited in Jurkat.ecoR cells that expressed Toso.HA (Figure 6a). Deletions of regions of the cytoplasmic domain of Toso from 334 to 390 still inhibited apoptosis. Moreover, a deletion of Toso lacking the entire cytoplasmic domain still retained substantial anti-apoptotic ability. Thus, the cytoplasmic domain of Toso is not absolutely required for the anti-apoptotic effects on Fas antibody-stimulated cells. (See Example 5, below) These results indicate that the homologies observed in the cytoplasmic region of Toso, as shown in Figure 3, are not the only sources of the anti-apoptotic signals generated by a Toso complex, although the cytoplasmic regions are required for enhancing the anti-apoptotic effects of Toso.

The Toso mutant lacking the transmembrane and cytoplasmic domains demonstrated that inhibition of Fas-induced apoptosis by Toso requires its insertion into membranes. As shown in Figure 6a, soluble Toso $\Delta$ (252-390).HA afforded no protection from apoptosis. Expression of the Toso $\Delta$ (252-390).HA protein was confirmed by western blot analysis of culture supernatants. Supernatants derived from pBabeMN-Toso $\Delta$ (252-390).HA-transfected 293T cells did not inhibit Fas-induced apoptosis, indicating that a membrane-proximal event dependent on *cis*--localization of Toso is required for blockade of the Fas-mediated death signal.

Many cell surface receptor complexes act through oligomerization and most immunoglobulin (Ig) domain proteins exist in homodimeric and heterodimeric Ig forms, functioning as self-assembling systems. Disruption of the Ig domain of Toso completely abrogated the anti-apoptotic ability of Toso (Toso $\Delta$ (29-187).HA). (See Figure 6a). Further, a chimeric  
5 Lyt-2Toso fusion protein in which the cytoplasmic domain of Toso was coupled to the extracellular and transmembrane region of Lyt-2- $\alpha'$  ( $\alpha'$  form of murine CD8 $\alpha$ , which forms homodimers at the cell surface) (Tagawa, *et al.*, (1986)) failed to inhibit Fas-induced apoptosis. Furthermore, anti-mouse CD8a mAb (Lyt-2) was used to crosslink the Lyt-2-Toso  
10 chimeras and induce multimerization of the Toso cytoplasmic domains. Toso.HA-expressing Jurkat.ecoR cells ( $5 \times 10^6$  cells) were incubated with 2 mM BS3 (PIERCE, Rockford, IL 61105, U.S.A.) for 1 hour at 4°C. After incubation, 1M Tris-HCl was added to a final concentration of 10 mM and cells were incubated for 15 minutes at 4°C. Whole-cell lysates were resolved by SDS PAGE, transferred to a membrane and processed with mouse  
15 monoclonal antihemagglutinin antibody (HA.11) (Babco) as described above. Jurkat.ecoR cells and Toso-expressing Jurkat.ecoR cells were used as controls. Jurkat.ecoR cells which expressed the chimeric Lyt-2-Toso fusion protein did not show any protection against anti-Fas mAb-induced apoptosis in presence of anti-mouse CD8 $\alpha$  mAb. These results suggest that some form of Ig domain mediated dimerization of Toso is required to initiate the  
20 anti-apoptotic effect in conjunction with the cytoplasmic region of Toso or other cell surface Toso-associating proteins. Cell surface molecules on Toso.HAexpressing Jurkat.ecoR cells were crosslinked using the water-soluble crosslinker, BS3 and apparent crosslinking molecular complexes at 150, 240, 300 kDa were detected (See Figure 6c). This result first indicates that Toso is a surface expressed receptor. The results are consistent with an  
25 association of Toso with another surface protein(s) of molecular weight 90 kDa. The several molecular weights observed for the crosslinked complexes are also minimally consistent with stoichiometric mixtures of 60 and 90 kDa molecules.

### **Domain Analysis of Toso suggests multiple interacting partners**

Deletion analysis of Toso indicated that surface expression of the immunoglobulin V-like region is necessary to inhibit Fas-induced-apoptosis and that the cytoplasmic domain of Toso

-42-

is insufficient and indeed partly expendable for the anti-apoptotic function. Deletion of the cytoplasmic domain resulted in abrogation of only about half of the anti-apoptotic effect. This suggests that Toso must be expressed at the cell surface in a manner where it presumably interacts other surface molecule(s) that propagate an anti-apoptotic signal. Most  
5 immunoglobulin family receptors are homo- or heterodimers that can become activated through ligand interactions. Crosslinking experiments revealed multiple potential higher-order complexes (150, 240, and 300 kDa), suggesting at least one partner of 90 kDa that interact with Toso. We suspect that Toso forms a heterodimer with this other surface protein to collaborate in initiating the anti-apoptotic signal that leads to cFLIP induction.  
10 Interactions of surface-expressed Toso complexes with ligands on or near target cells might also modulate the ability of Toso to provide anti-apoptotic signaling. We are currently investigating the existence of such ligands and contributory molecules.

A model summarizing the results is shown in Figure 10. In this model, stimulation through of the T cell receptor complex transmits activation signals leading to upregulation of Fas and  
15 FasL. Activation also induces Toso expression, providing the potential for anti-apoptotic signals that protect against Fas-mediated apoptosis. Toso accomplishes this by forming homo- or heterodimers at the cell surface to generate signals that inhibit the initiation or propagation of caspase-8 activation by cFLIP. It is also possible that Toso requires an extracellular ligand that might modulate its activities. The signaling pathway activated by  
20 Toso is clearly important as it leads to induced expression of cFLIP (Irmeler, *et al.* (1997); Srinivasula, *et al.* (1997)).

#### EXAMPLE 4

##### **T Cell Signaling Leading to Apoptosis Is Blocked by Activated Toso.**

Poly (A)<sup>+</sup> RNA was prepared from Jurkat cells or Jurkat cells stimulated for 24 hours with 10  
25 ng/ml of phorbol 12-myristate 13-acetate (PMA; SIGMA Chemical Company, MO 63178, U.S.A.) and 1 µg/ml phytohemagglutinin (PHA; SIGMA) or 10 ng/ml PMA and 500 ng/ml ionomycin (SIGMA). Poly (A)<sup>+</sup> RNA (5µg) was subjected to electrophoresis through 1% agarose gel containing 2.2 M formaldehyde, and transferred to Hybond N<sup>+</sup> membrane

(Amersham Life Science Inc., IL 60005, U.S.A.). Hybridization was carried out according to the manufacturer's recommendation. A specific probe for the Toso coding region (1.2 kbp) was synthesized with PCR from pBabeMN-Toso using 5'-AGG GGC TCT TGG ATG GAC (TosoS) and 5'-CTG GGG TTG GGG ATA GC (TosoA). As a control probe, the human  $\beta$ -actin cDNA control probe (CLONTECH Laboratories, Inc., CA 94303-4230) was used. Probes were labeled with  $^{32}\text{p}$  using a random-primed labeling kit, Prime-a-Gene (Promega). Human RNA Master Blot and Human Immune System Multiple Tissue Northern Blot II (CLONTECH Laboratories) were used to survey Toso mRNA expression in several human tissues. Toso expression was observed in lymph nodes, lung and kidney. In addition to these tissues, we detected faint signals from spleen, thymus, liver, heart and salivary gland. Tissues which were analyzed for Toso mRNA include: A1: Whole brain, A2: Amygdala, A3: Caudate nucleus, A4: Cerebellum, A5: Cerebral cortex, A6: Frontal lobe, A7: Hippocampus, A8: Medulla oblongata, B1: Occipital lobe, B2: Putamen, B3: Substantia nigra, B4: Temporal lobe, B5: Thalamus, B6: Subthalamic nucleus, B7: Spinal cord, C1: Heart, C2: Aorta, C3: Skeletal muscle, C4: Colon, C5: Bladder, C6: Uterus, C7: Prostate, C8: Stomach, D1: Testis, D2: Ovary, D3: Pancreas, D4: Pituitary gland, D5: Adrenal gland, D6: Thyroid gland, D7: Salivary gland, D8: Mammary gland, E1: Kidney, E2: Liver, E3: Small intestine, E4: Spleen, E5: Thymus, E6: Peripheral leukocyte, E7: Lymph node, E8: Bone marrow, F1: Appendix, F2: Lung, F3: Trachea, F4: Placenta, G1: Fetal brain, G2: Fetal heart, G3: Fetal kidney, G4: Fetal liver, G5: Fetal spleen, G6: Fetal thymus, G7: Fetal lung. (Figure 7a). Using Human Immune System Multiple Tissue Northern Blot II, and film exposed at  $-70^{\circ}\text{C}$  with an intensifying screen for one day, endogenous Toso mRNA species of 2.0 (major), 2.8, 3.5 and 4.3 kbp were detected in lymph node and spleen (see Figure 7b). The nucleotide length of the cDNA was 1.9 kbp, suggesting that the additional bands might either be alternative splice products or incompletely processed messages. Toso expression was also observed in peripheral blood leukocytes, thymus (Figure 7b). Expression in bone marrow and fetal liver was much lower than that in lymph node and spleen, as seen after overexposure of the blot (data not shown).

The expression of Toso in several human cell lines was analyzed by semi-quantitative RT-PCR involving amplification of the 1.2 kbp-coding region of Toso (Figure 7c). The first strand of cDNA was synthesized with 10 µg total RNA from several human cell lines and peripheral blood mononuclear cells. PCR was performed for 35 cycles using TosoS and TosoA. After an initial denaturation at 94°C for 5 minutes, each cycle of amplification consisted of 30 second denaturation at 94°C, followed by a 30 second-annealing at 58°C and 2 minutes extension at 72°C. After 35 cycles, the final product was extended for 10 minutes at 72°C. PCR products were electrophoresed through 1.0% agarose gel and transferred to Hybond N+ membrane. The BamHI-XhoI fragment (510 bp) of the Toso-coding region were labeled with <sup>32</sup>p. Hybridization was carried out as described above. To detect cFLIP mRNA expression, a 1.1 kbp fragment (998-2061) of the cFLIP gene (U97074) was amplified with primers 5'-GGG AGA AGT AAA GAA CAA AG and 5'-CGT AGG CAC AAT CAC AGC AT for 35 cycles as described above. The sequence of the 1.1 kbp PCR product was verified using cycle sequencing ready reaction kit (Perkin Elmer, CA 94404, U.S.A.). As a control, β-actin cDNA was amplified for 15 and 25 cycles as described above.

Toso mRNA was detected in lymphoid cell lines such as Jurkat cells (T cell leukemia), a kind gift from Dr. Kuo, Harvard Univ., CemT4 cells (T cell leukemia), MolT-4 cells (T cell leukemia), HB11.19 cells (B cell lymphoma), a kind gift from Dr. Cleary, M. L., Stanford Univ., and Reh cells (acute lymphocytic leukemia; non T; non B, ATCC). HL-60 cells (promyelocytic leukemia, ATCC) displayed a consistently weak signal. In contrast, Toso PCR products were not detected in non-hematopoietic cell lines including HepG2 cells (hepatoblastoma, a kind gift from Dr. Blau, Stanford Univ.), 293 cells (kidney; transformed with adenovirus, ATCC) and Hela cells (cervix; adenocarcinoma, ATCC). Toso therefore is constitutively expressed in cells of hematopoietic cells.

Poly (A)<sup>+</sup> RNA was prepared from Jurkat cells stimulated for 24 hours with 10 ng/ml PMA (SIGMA) and 500 ng/ml Ionomycin (SIGMA). The first strand of cDNA was synthesized with 10 µg Poly (A)<sup>+</sup> RNA using oligo-dT primers and performed PCR with primers, 5'-AGA ATT CTC TCT AGG GGC TCT TGG ATG (See Figure 1 where the EcoRI site is

underlined) and 5'-ATA AAG CTT CTC AGG GCA CAG ATA GAT GG (HindIII site is underlined), which were located 23 bp and 136 bp nucleotides upstream and downstream of the Toso coding region, respectively. The 1.3 kbp fragment was ligated into pBluescript SK(+). Five independent clones were picked up and sequenced using cycle sequencing ready  
5 reaction kit (Perkin Elmer). The deduced amino-acid sequences from the five independent clones were completely identical to the gene from the cDNA library screening, although two silent mutations were found within the original gene as compared to the PCR consensus sequences.

Toso was expressed in several human cell lines including Jurkat cells, CemT4 cells (human T  
10 cell leukemia), SupT1 cells (human T cell leukemia, a kind gift from Dr. Cleary, M. L., Stanford Univ.), Oli-Ly8 cells (human B cell line; transformed with EBV), AMK cells (human B cell line; transformed with EBV), both a gift from Dr. Negrin, R. S., Stanford Univ., Reh cells (acute lymphocytic leukemia; non T; non B), HL-60 cells (promyelocytic leukemia) and HepG2 cells (hepatoma) using pBabeMN-Toso IRKS neo to allow  
15 cotranslational selection with Geneticin (GIBCO BRL). All of the human T cell lines and one of the human B cell lines, Oli-Ly8 cells, in which Toso was overexpressed, were inhibited for apoptosis induced by anti-Fas mAb, whereas no significant protection was observed against Fas-induced apoptosis in the other cell lines (data not shown). Thus, the anti-apoptotic effect of Toso also is limited to certain classes of hematopoietic cells,  
20 suggesting the presence of tissue-specific mediators in these cells.

T cell activation results in increased expression of Fas and FasL on the cell surface. This is paradoxical, as it is clear that T cells do not kill themselves after such induction, whereas overexpression of Fas and FasL in other cell types does lead to cell death. *In vitro*, PMA and Ionomycin can induce apoptosis in T cells (Oyalzu, *et al.*, Biochem. Biophys. Res. Commun.,  
25 **213**:994-1001 (1995)) by mimicking certain aspects of CD3 engagement, including upregulation of Fas and FasL. One function of Toso might be to inhibit T cell activated self-killing and that the levels of Toso might become increased following T cell activation, helping to render Jurkat cells partially resistant to upregulated Fas and FasL. Expression of

Toso mRNA in Jurkat cells was examined by northern hybridization. As shown in Figure 8a, an endogenous Toso mRNA species of 2.8 kbp was detected in resting Jurkat cells, although expression was seen after overexposure of the blot (data not shown). Toso mRNA expression increased, including minor species (2.0, 3.5, 4.3, 5.5 kbp), after stimulation of Jurkat cells with PMA and PHA (15-fold increase) or PMA in combination with ionomycin (25-fold increase). Thus, Toso can be induced following T-cell activation.

Jurkat.ecoR cells, Jurkat.ecoR cells infected with pBabeMN-lacZ, and pBabeMN-Toso-infected clones were precultured with 10 ng/ml PMA and 500 ng/ml ionomycin for 12 hours and then incubated with 10 ng/ml of anti-Fas mAb for 24 hours, and as shown in Figure 8b, Jurkat cells were susceptible to anti-Fas mAb-induced apoptosis as well as PMA/ionomycin-induced apoptosis. However, following activation with PMA/ionomycin one third of Jurkat cells were clearly resistant to anti-Fas mAb induced apoptosis. These results suggest that Jurkat cells activate a protective system that blocks Fas-mediated apoptosis, supporting the contention that induced Toso is a mediator in this protective effect.

We further tested whether Toso expression could rescue activation-induced programmed cell death. We randomly picked five pBabeMN-Toso-infected Fas resistant Jurkat T cell clones and used these to assay the inhibitory effect of Toso on PMA/ionomycin-induced apoptosis. All five clones exhibited significant resistance to PMA/ionomycin-induced apoptosis, as well as continued strong resistance to Fas-induced apoptosis (Figure 8c). Control clones displayed the expected killing effect when activated with PMA and ionomycin. Toso not only inhibited apoptosis activated by Fas and TNF- $\alpha$ , but also inhibited apoptosis induced by certain classes of T cell activation events.

Normal T cells at early stages of activation are resistant to Fas-induced apoptosis but become Fas sensitive at late stages of activation (Klas, *et al.*, (1993)). Toso expression kinetics in peripheral blood mononuclear cells were examined after PHA stimulation using by semi-quantitative RT-PCR. Peripheral blood leucocyte (PBL) from healthy volunteers were isolated by Histopaque-1077 (Sigma) density centrifugation. Adherent cells were removed



by adherence to plastic culture vessels. Cells were activated with phytohemagglutinin (PHA)-P (1 µg/ml) for 24 hours washed, and cultured with 20 U/ml of recombinant human IL-2 (R&D Systems Inc., Minneapolis, MN 55413, U.S.A.). To perform mixed lymphocyte culture, PBL were treated with 20 µg/ml of mitomycin-C (stimulating cells, SC) for 3 hours and washed. SC were adjusted to  $7 \times 10^5$  cells/ml and cultured with an equal volume and cell density of PBL (responding cells, RC) from another donor (Clot, *et al.*, Immunology, **29**:445-453 (1975)). Cells were cultured for one to seven days (day 1, 3, 5, and 7). Toso expression was observed at day 1 and upregulated expression at day 3 after activation. However, Toso expression was clearly decreased at days 5 (Figure 9a), correlating with Fas sensitivity studies (Klas, *et al.* (1993)). Further, allogenic stimulation in mixed lymphocyte cultures was performed to determine whether Toso is activated in primary immune cells upon T cell activation. As shown in Figure 9b, Toso expression was also rapidly induced in the presence of stimulator cells on day 1; however Toso expression in mixed lymphocyte cultures was reduced by day 6 to levels even lower than seen on day 1 and responder cells alone at day 6. These results further confirm a supportive role for Toso induced resistance to Fas-mediated death during T lymphocyte activation.

Natural T cell resistance to Fas-induced apoptosis shows a time-dependent kinetics (Klas, *et al.* (1993)). By day 6 post-activation, T cells become susceptible to Fas-induced death. In addition, activation of Jurkat cells by PMA/ionomycin induces a significant increase in Fas ligand expression which is thought to promote apoptosis (Oyalzu, *et al.* (1995); Brunner, *et al.*, Nature, **373**:441-444 (1995)). However, PMA/ionomycin-activated Jurkat cells were not as efficiently induced to undergo apoptosis by anti-Fas mAb treatment compared to unstimulated Jurkat cells (Figure 8b). This suggested that Jurkat cells become at least partly resistant to anti-Fas mAb-induced apoptosis after T cell signaling, mimicking processes observed in natural T cells. mRNA expression of Toso in Jurkat cells, as well as in peripheral T cells, is strongly upregulated upon stimulation with T cell activators. Further, overexpression of Toso protected Jurkat cells against PMA/ionomycin- induced apoptosis.

This is consistent with the proposal that Toso expression, which transiently increased and then decreased in peripheral blood mononuclear cells after activation with PHA or allogenic stimulation, is responsible for the temporary Fas resistance in T cells. Hence, the results are consistent with the hypothesis that Toso may be involved in activation-induced resistance to apoptosis of T cells during an immune response. We conclude from the results that the inhibitory effect of the extracellular domain of Toso in activation-induced apoptosis is attributable to the inhibition of Fas-mediated signal transduction through inhibition of caspase-8 by c-FLIP induction.

The finding that Toso can exert cell-specific and signaling pathway specific effects on apoptosis suggests that other polypeptides exist that act upon the Fas death induction cascade. Critically, the fact that signalling by the extracellular domain of Toso induces expression of cFLIP suggests the existence of a regulatable transcription cascade that can be activated to block Fas-mediated apoptosis in some cell types. As shown here, high efficiency gene transduction using a retroviral approach, like other cDNA cloning approaches (Vito, *et al.*, Science, **271**:521-525 (1996); Kitamura, *et al.*, Proc. Natl. Acad. Sci., **92**:9146-9150 (1995)), allows functional cloning of genes with high throughput and accuracy. Further analysis of the Toso pathway coupled with gene disruption analysis in animals will further clarify the overall role that the extracellular domain of Toso plays in modulating activation-induced T-cell apoptosis *in vivo*.

#### EXAMPLE 5

##### **The Cytoplasmic Domain of Toso Promotes Cell Death in Murine pre-B Cells.**

70Z/3 cells were incubated with virus at 32°C for 12 hours including initial spinning and achieved 70-80 % infection efficiency estimated using FACS analysis for pBabeMN-Lyt-2 $\bar{O}$ . 70 Z3 cells kept about 80% viability at the end of 12 hours incubation with virus. However, after infection, we observed rapid cell death (about 70 % of cells were dead) in 70Z/3 cells infected with pBabeMN-TOSO, not in 70 Z3 cells with pBabeMN- Lyt-2 $\bar{O}$  nor with supernatant of  $\phi$ NX-E cells (Figure 11). Supernatant from pBabeMN-TOSO transfected 293T cells, which is the parental cell line of  $\phi$ NX-E and  $\phi$ NX-A cells, did not induce rapid

cell death to 70Z/3 cells. These results suggest that gene products of TOSO induced rapid cell death. Most dead cells after infection showed apoptotic nuclei under microscopic observation, suggesting TOSO induced apoptosis to 70Z/3 cells.

To clarify which region was responsible for apoptotic signal transduction, a set of deletion mutants of the TOSO cDNA was prepared as shown in Example 3. The mutated TOSO cDNA was ligated into pBabeMN retroviral vector and infected 70Z/3 cells. As shown in Table A, below, massive cell death was observed in 70Z/3 cells infected with pBabeMN-TOSO.HA, -TOSO $\Delta$ (377-390).HA, -TOSO $\Delta$ (334-390).HA and Lyt-2/TOSO(271-390).HA, but not pBabeMN-TOSO $\Delta$ (252-390).HA and pBabeMN-TOSO $\Delta$ (29-187).HA. Full length Lyt-2 did not induce rapid cell death to 70Z/3 cells after infection (data not shown). Lyt-2/TOSO(271-390).HA. was most effective in promoting cell death in 70Z/3 cells, suggesting that the cytoplasmic region was responsible for massive cell death in 70 Z3 cells.

The TOSO-induced cell death in 70Z/3 cells, suggests that TOSO works not only for protection against Fas-induced apoptosis but also for promotion of cell death. The cytoplasmic domain from A<sup>281</sup> to A<sup>333</sup> is responsible for promotion of cell death. BLAST search reveals that this region has partial homology to FAST kinase and acid sphingomyelinase which is involved in Fas-induced apoptosis. When the cytoplasmic domain of TOSO is compared to the "death domain" from several molecules, the cytoplasmic domain of TOSO did not show any homology to known "death domain", including the consensus sequence as described. The promotion of cell death by TOSO was not observed in several cell lines. Cell death induced by TOSO may be observed in some stages of B cell development.

Table A indicates the effect of TOSO deletion mutants on promotion of apoptosis. 70Z/3 cells were infected with pBabeMN-Lyt-2 $\alpha$ .HA, pBabeMN-TOSO.HA, pBabeMN-TOSO $\Delta$ (377-390).HA, pBabeMN-TOSO $\Delta$ (334-390).HA, pBabeMN-TOSO $\Delta$ (281-390).HA,

pBabeMN-TOSO $\Delta$ (252-390).HA and pBabeMN-TOSO $\Delta$ (29-187).HA. After infection, the stained cells were incubated with phosphate-buffered saline including 100  $\mu$ g/ml of ethidium bromide (SIGMA) and 100  $\mu$ g/ml of acridine orange (SIGMA). Viable cells were identified with UV microscopy. The percentage of viable cells is expressed as mean  $\pm$  SD of triplicate cultures.

Infected-Virus Encoding	% Viable Cells
Lyt-2.HA	73 $\pm$ 5
4.8.HA	30 $\pm$ 4
4.8 $\Delta$ (377-390).HA	31 $\pm$ 5
4.8 $\Delta$ (334-390).HA	29 $\pm$ 2
4.8 $\Delta$ (281-390).HA	75 $\pm$ 2
4.8 $\Delta$ (252-390).HA	78 $\pm$ 3
4.8 $\Delta$ (29-187).HA	83 $\pm$ 3
Lyt-2/4.8(271-390).HA	5 $\pm$ 3

CLAIMS

We claim:

1. A recombinant nucleic acid encoding a Toso protein that will hybridize under high stringency conditions to the nucleic acid sequence depicted in Figure 1 (SEQ ID NO:1) or its complement.
2. A recombinant nucleic acid encoding a Toso protein that is at least about 70% identical to the amino acid sequence depicted in Figure 1 (SEQ ID NO:1).
3. A recombinant nucleic acid according to claim 2 that is at least about 70% identical to the nucleic acid sequence depicted in Figure 1 (SEQ ID NO:1) or its complement.
4. A recombinant nucleic acid according to claim 1 wherein said Toso protein is a human Toso protein.
5. A recombinant nucleic acid according to claim 1 encoding the amino acid sequence depicted in Figure 1 (SEQ ID NO:1).
6. A recombinant nucleic acid according to claim 1 encoding a Toso polypeptide that is at least about 70% identical to the sequence of amino acid residues 18 to 253 of Figure 2a (SEQ ID NO:2).
7. A recombinant nucleic acid according to claim 1 having at least 70% sequence identity to (a) a DNA molecule encoding a Toso polypeptide comprising the sequence of amino acid residues 18 to 253 of Figure 2a (SEQ ID NO:2), or (b) the complement of the DNA molecule of (a).

8. A recombinant nucleic acid according to claim 1 encoding a Toso polypeptide that is at least about 70% identical to the sequence of amino acid residues 18 to 272 of Figure 2a (SEQ ID NO:2)
- 5 9. A recombinant nucleic acid according to claim 1 having at least 70% sequence identity to (a) a nucleic acid molecule encoding a Toso polypeptide comprising the sequence of amino acid residues 18 to 272 of Figure 2a (SEQ ID NO:2), or (b) the complement of the nucleic acid molecule of (a).
- 10 10. A recombinant nucleic acid according to claim 1 encoding a Toso polypeptide that is at least about 70% identical to the sequence of amino acid residues 273 to 390 of Figure 2a (SEQ ID NO:2).
11. A recombinant nucleic acid according to claim 1 comprising DNA having at least 70% sequence identity to (a) a nucleic acid molecule encoding a Toso polypeptide comprising the sequence of amino acid residues 273 to 390 of Figure 2a (SEQ ID NO:2), or (b) the complement of the nucleic acid molecule of (a).
- 15 12. A recombinant nucleic acid according to claim 1 operably linked to control sequences recognized by a host cell transformed with the nucleic acid.
13. An expression vector comprising the nucleic acid of claim 12.
14. A host cell comprising the recombinant nucleic acid of claim 1.
15. A host cell comprising the vector of claim 13.
- 20 16. A process for producing a Toso protein comprising culturing the host cell of claim 14 under conditions suitable for expression of a Toso protein.

17. A process according to claim 16 further comprising recovering said Toso protein.

18. A Toso protein encoded by a nucleic acid that will hybridize under high stringency conditions to the complement of the nucleic acid sequence depicted in Figure 1 (SEQ ID NO:1).

5 19. A recombinant Toso protein that is at least about 70% identical to the amino acid sequence depicted in Figure 2a (SEQ ID NO:2).

20. A Toso protein according to claim 18 comprising the sequence depicted in Figure 2a (SEQ ID NO:2).

10 21. A Toso protein according to claim 18 encoded by a nucleic acid at least about 70% identical to the nucleic acid sequence depicted in Figure 1 (SEQ ID NO:1).

22. An isolated polypeptide which specifically binds to a Toso protein according to claim 18.

23. A polypeptide according to claim 22 that is an antibody.

24. A polypeptide according to claim 23 wherein said antibody is a monoclonal antibody.

15 25. A monoclonal antibody according to claim 24 that modulates the biological function of a Toso protein.

26. A monoclonal antibody according to claim 25 that reduces or eliminates the biological function of a Toso protein.

27. A monoclonal antibody according to claim 24 that increases the biological function of a Toso protein.

28. An antibody according to claim 23 directed against the extracellular domain of the Toso protein comprising the sequence of amino acid residues 18 to 253 of Figure 2a (SEQ ID NO:2).

29. An antibody according to claim 23 directed against the cytoplasmic domain of the Toso protein comprising the sequence of amino acid residues 273 to 390 of Figure 2a (SEQ ID NO:2).

30. A method of modulating apoptosis in a cell comprising administering to said cell a recombinant nucleic acid encoding a Toso protein.

31. A mammalian cell comprising a modified Toso cell surface receptor.

32. A method for treating an apoptosis related condition in a mammal comprising administering a recombinant nucleic acid encoding a Toso protein.

33. A method for treating an apoptosis related condition in a mammal comprising administering a Toso protein.

34. A method for treating an apoptosis related condition in a mammal comprising administering an anti-Toso antibody.



1 / 10

aaaggagtaagcagcgtgtctccatccccctctctaggggtcttgg ATGGACCTTGCACTCTAGAAGGACAATGGACT  
TCTGGCTTTGGCCACTTTACTTCTCTGCCAGTATCAGGGGCCCTG AGGATCCTCCAGAAAGTAAAGGTAGAGGGGGAGCTG  
 GGGGATCAGTTACCATCAAAATGCCCACTTCTCTGAAATGCATGTGAGGATATATCTGTGCCGGGAGATGGCTGGATCTGG  
 AACATGTGGTACCGTGGTATCCACCAACCAACTTCATCAAGGCAGAAATACAAGGCCGAGTTACTCTGAAGCAATACCCAC  
 GCAAGAACTCTGTTCCTAGTGGAGGTAACACAGCTGACAGAAAGTGACAGCGGAGTCTATGCCCTGCGGAGCGGGCATGAAC  
 ACAGACCGGGGAAAGACCCAGAAAGTCAACCTGAATGTCCACAGTGAATACGAGCCATCATGGGAAGAGCAGCCAATGCC  
 TGAGACTCCAAAATGGTTTCATCTGCCCCATATTTGTTCAGATGCCCTGCATATGCCAGTTCTTCCAAATTCGTAACCAAGAG  
 TTACCACACCAGCTCAAAGGGCAAGTCCCTCCAGTTCACCACTCCTCCCCACCAACCAATCAACCCGCCCTCGA  
 GTGTCCAGAGCATCTTCAGTAGCAGGTGACAAGCCCCGAACCTTCTCTGCCATCCACTACAGCCTCAAAAATCTCAGCTCT  
 GGAGGGCTGCTCAAGCCCCAGACGCCCAGCTACAACCAACCAAGGCTGCACAGGCAGAGACACTGGACTATGGCT  
 CACAGTCTGGGAGGGAAGGCCAAGGA TTTCACATCTGTGATCCCGACCATCCTGGGCCTTTTCCTGCTGGCACTTCTGGGG  
CTGGTGGTGAAAGGGCGTTGAAAGGAGG AAAGCCCTCTCCAGCGGGCCCCGCGACTGGCCGTGAGGATGCGCGCCCT  
 GGAGAGTCCCAGAGGCCCGGGGTGCGCGGACCGCGCTCCCAAACAATCTACAGCGCTGCCCGGGCGCGCTC  
 GTGGAGCGGACGCTGCAGGCACAGGGGAGGCCCCCGTTCCCGCCCCGGAGCGCGCTTGCCCCCGCCCCGCTGCAGGTG  
 TCTGAATCTCCCTGGCTCCATGCCCCCATCTCTGAAGACCAGCTGTGAATACGTGAGCCTCTACCACCCAGCCTGCCGCCAT  
 GATGGAGGACAGTGATTCAGATGACTACATCAATGTTCTCTGCCCTGA caactccccagctatcccccaacccccaggctcgg  
 actgtggtgccaaggagtctcatctatctgtgatgtccaatacctgcttcatgtgttctcagagccctcatcactccc  
 atgccccatctcgactcccatcccatctatctgtgccctgagcatggctctgccccaggctgtcttgacacacctggc  
 agccccctgtagttgacaggttaagctgtaggcatgtagagcaattgtcccaatgccacttgcttcccttccaagccgtcg  
 aacagactgtgggatttgagagtgtttcttccatgtctttgaccacaggggtgtgtgctgcccaggctctagatcacatg  
 gcatcaggctggggcagagcatagctattgtctcgggcacaccttcccagggttgggtcttacacaaatagaaggctctt  
 gctctgagttatgtgacgtgcctcagccccatggactaagcaggggtctggataaaaaaacactcctggaaacgcctttgc  
 cctgatccaaatgttagcacttgctagtgaagctctacttatctcaagttctatgctaaaggcaatttatcttcatgtga  
 tgataaaccacaaacttattagcaagatatgcataatatatccataaattctcttactctgtctcctcatcctt

**FIG.\_1**


Cording region: Capitalized

Leader sequence: Underlined

Transmembrane region: Double underlined

2 / 10

1 MDFWLWPLYF LPVSGALRIL PEVKVEGELG GSVTIKCPLP EMHVRIYLCR  
 51 EMAGSGTCGT VVSTTNFIKA EYKGRVTLKQ YPRKNLFLVE VTQLTESDSG  
 101 VYACGAGMNT DRGKTQKVTL NVHSEYEPSW EEQPMPEPK WFHLPYLFQM  
 151 PAYASSSKFV TRVTTPAQRG KVPPVHHSSP TTQITHRPRV SRASSVAGDK  
 201 PRTFLPSTTA SKISALEGLL KPQTPSYNHH TRLHRQRALD YGSQSGREGQ  
 251 GFHILIPTIL GLFLLALLGL VVKRAVERRK ALSRRARRLA VRMRALESSQ  
 301 RPRGSPRPRS QNNIYSACPR RARGADAAGT GEAPVPGPGA PLPPAPLQVS  
 351 ESPWLHAPSL KTSCEYVSLY HQPAAMMEDS DSDDYINVPA

**FIG. 2a**









FIG.-3

4 / 10


**FIG. 4a**



**FIG. 4b**




**FIG. 4c**




**FIG. 4d**


5 / 10

**FIG.\_4e**Relative cell  
number


GFP expression

Relative cell  
number


GFP expression

Relative cell  
number

GFP expression




**FIG.\_5a**




**FIG.\_5b**


**FIG.\_6b**




**FIG.\_6c**




7 / 10




8 / 10




**FIG.\_7a**




**FIG.\_7b**




**FIG.\_7c**



**FIG.\_8a**






**FIG.\_9a**




**FIG.\_9b**



9 / 10





**FIG. 10**

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/24391

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/13 C07K14/705 C07K16/28 A61K38/17

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	HITOSHI Y ET AL: "Toso, a cell surface, specific regulator of Fas-induced apoptosis in T cells." IMMUNITY, (1998 APR) 8 (4) 461-71. JOURNAL CODE: CCF. ISSN: 1074-7613., XP002100823 United States see figure 1	1-21
E	EP 0 905 238 A (SMITHKLINE BEECHAM CORP) 31 March 1999 see page 6 - page 9 --- -/--	1-30, 32-34



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

\* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

22 April 1999

Date of mailing of the international search report

06/05/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Espen, J

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/24391

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,A	<p>ROTHENBERG, S. MICHAEL ET AL:            "Intracellular combinatorial chemistry            with peptides in selection of caspase-like            inhibitors"            NATO ASI SER., SER. H (1998), 105(GENE            THERAPY), 171-183 CODEN: NASBE4;ISSN:            1010-8793, XP002100824            -----</p>	

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 98/24391

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claims 30,32-34  
are directed to a method of treatment of the human/animal  
body, the search has been carried out and based on the alleged  
effects of the compound/composition.
2. ☒ Claims Nos.: 31  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such  
an extent that no meaningful International Search can be carried out, specifically:  
Claim 31 relates to a Toso cell surface receptor. Said receptor is not  
characterized by true technical features. In consequence, the scope of said  
claim is ambiguous and, moreover, the subject-matter thereof is vague and  
not sufficiently disclosed
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all  
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment  
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report  
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is  
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

### Information on patent family members

International Application No.

PCT/US 98/24391

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0905238      A	31-03-1999	NONE	